var title_f33_14_34016="Stocking immersion";
var content_f33_14_34016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stocking immersion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pattern of deep symmetrical burns in a stocking distribution is typical for inflicted immersion injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Stephen Ludwig, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34016=[""].join("\n");
var outline_f33_14_34016=null;
var title_f33_14_34017="Ocular lubricant: Pediatric drug information";
var content_f33_14_34017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ocular lubricant: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10360984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Akwa Tears&reg; [OTC];",
"     </li>",
"     <li>",
"      Refresh&reg; Lacri-Lube&reg; [OTC];",
"     </li>",
"     <li>",
"      Tears Renewed&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Lubricant, Ocular",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Neonatal data are unavailable. Dose extrapolated from older patients. Ophthalmic: Apply",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo; of ointment to the inside of the lower lid as needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, Adolescents, and Adults: Ophthalmic: Apply",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     &rdquo; of ointment to the inside of the lower lid as needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F245463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic:  (1 g [DSC], 3.5 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Akwa Tears&reg;: 3.5 g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tears Renewed&reg;: 3.5 g (3.5 g)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Do not use with contact lenses; to avoid contamination, do not touch tip of container to any surface",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store away from heat",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular lubricant",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F14198756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular: Temporary blurring of vision, irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue if eye pain, vision change, redness or eye irritation occurs or if condition worsens or persists &gt;72 hours",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms an occlusive film on the surface of the eye to lubricate and protect the eye from drying",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains petrolatum, mineral oil, chlorobutanol and lanolin alcohols",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12656 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34017=[""].join("\n");
var outline_f33_14_34017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10360984\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049011\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675256\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049008\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F245463\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049014\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049010\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049013\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198756\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049016\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049007\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049006\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049017\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12656|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_14_34018="Port placement for laparoscopic cholecystectomy";
var content_f33_14_34018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Port placement for laparoscopic cholecystectomy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An open (Hasson) technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and three additional 5 mm ports are placed under direct vision 1 to 2 cm inferior to the right subcostal margin. The surgeon operates from the patient's left side using subxiphoid and typically the medial subcostal port (shown in red). The assistant works from patient's right side using the lateral subcostal port and periumbilical port (shown in blue).",
"    <br>",
"     <br>",
"      The surgeon manipulates the infundibulum of the gallbladder to provide counter-retraction with the left hand and uses a dissector with the right hand through the subxiphoid port. The assistant uses the left hand to retract the fundus superiorly and operates the camera with the right hand. The gallbladder is usually removed through the umbilical port.",
"      <div class=\"footnotes\">",
"       * Port placement and technique may vary amongst laparoscopic surgeons.",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34018=[""].join("\n");
var outline_f33_14_34018=null;
var title_f33_14_34019="Pancreatic necrosis CT";
var content_f33_14_34019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pancreatic necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abdominal computed tomography (CT) showing a large area of infected pancreatic necrosis (arrow). The necrosis developed after severe acute pancreatitis with pancreatic duct disruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34019=[""].join("\n");
var outline_f33_14_34019=null;
var title_f33_14_34020="Lidocaine and hydrocortisone: Drug information";
var content_f33_14_34020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/0/18436?source=see_link\">",
"    see \"Lidocaine and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AnaMantle HC&reg; Cream;",
"     </li>",
"     <li>",
"      AnaMantle HC&reg; Forte;",
"     </li>",
"     <li>",
"      AnaMantle HC&reg; Gel;",
"     </li>",
"     <li>",
"      LidaMantle HC&reg;;",
"     </li>",
"     <li>",
"      LidaMantle HC&reg; Relief Pad&trade;;",
"     </li>",
"     <li>",
"      LidoCort&trade;;",
"     </li>",
"     <li>",
"      Peranex&trade; HC;",
"     </li>",
"     <li>",
"      Peranex&trade; HC Medi-Pad;",
"     </li>",
"     <li>",
"      RectaGel&trade; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F188715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anesthetic/Corticosteroid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F188706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory/anesthetic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: One applicatorful twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F188707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, rectal: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (7 g); lidocaine hydrochloride 3% and hydrocortisone acetate 1% (7 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AnaMantle HC&reg; Forte: Lidocaine hydrochloride 3% and hydrocortisone acetate 1% (7 g) [contains propylene glycol; kit contains 20 tubes (7 g each), 20 single-use applicators, and 20 single-use wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AnaMantle HC&reg;: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (7 g) [contains propylene glycol; kit contains 14 single-use tubes (7 g each) and 14 applicators]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peranex&trade; HC: Lidocaine hydrochloride 2% and hydrocortisone acetate 2% (7 g) [contains propylene glycol; kit contains 24 single-use tubes with built-in applicators (7 g each) and 24 cleansing wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (30 g) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle HC&reg;: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal: Lidocaine hydrochloride 3% and hydrocortisone acetate 2.5% (7 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AnaMantle HC&reg;: Lidocaine hydrochloride 3% and hydrocortisone acetate 2.5% (7 g) [contains propylene glycol; kit contains 20 single-use tubes with applicators (7 g each) and 20 cleansing wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidoCort&trade;: Lidocaine hydrochloride 3% and hydrocortisone acetate 2.5% (7 g) [contains propylene glycol; kit contains 20 single-use tubes with applicators (7 g each) and 20 cleansing wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RectaGel&trade; HC: Lidocaine hydrochloride 2.8% and hydrocortisone acetate 0.55% (20 g) [contains propylene glycol; kit contains 5 tubes (20 g each) and 15 single-use applicators]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle HC&reg;: Lidocaine hydrochloride 3% and hydrocortisone acetate 0.5% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LidaMantle HC&reg; Relief Pad&trade;: Lidocaine hydrochloride 2% and hydrocortisone acetate 2% (60s) [6 mL solution/pad]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peranex&trade; HC Medi-Pad: Lidocaine hydrochloride 3% and hydrocortisone acetate 1% (60s) [6 mL solution/pad]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes lotion, pad",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F188695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply thin film to affected area; avoid use of occlusive dressings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Applicator tip should be gently inserted into the anal area; apply to areas of discomfort and anal opening. Do not completely insert applicator and tube; do not insert deep in the anus or rectum.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F188694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical anti-inflammatory and anesthetic for skin disorders; rectal for the treatment of hemorrhoids, anal fissures, pruritus ani, or similar conditions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F188698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine, hydrocortisone, local anesthetics of the amide type, corticosteroids, or any component of the formulation; topical tuberculous, viral or fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F188684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal (HPA) axis suppression (reversible) particularly in younger children. HPA axis suppression may lead to adrenal crisis. Risk is increased when used over large surface areas, for prolonged periods, or with occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Discontinue if infection occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Adverse systemic effects including hyperglycemia, glycosuria, fluid and electrolyte changes, and HPA suppression may occur when used on large surface areas, for prolonged periods, or with an occlusive dressing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Class I antiarrhythmics: Use with caution in patients taking class I antiarrhythmics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Application site: For external use only; avoid contact with eyes, nose, or ears.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F188713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F188709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F188699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (LidaZone HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.5% (7 g): $5.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lidocaine-Hydrocortisone Ace Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-0.5% (7 g): $17.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Lidocaine-Hydrocortisone Ace Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.8-0.55% (100 g): $144.30",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F188697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/14/34020/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10121 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34020=[""].join("\n");
var outline_f33_14_34020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188703\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188715\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188706\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188707\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188692\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188681\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188695\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188694\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188698\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188684\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188713\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188687\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188689\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188700\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188709\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188699\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188697\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10121\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10121|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/0/18436?source=related_link\">",
"      Lidocaine and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_14_34021="Genotyping HPV HR and cytology in women 30 and over";
var content_f33_14_34021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 649px\">",
"   <div class=\"ttl\">",
"    Use of HPV genotyping to manage HPV HR * positive / cytology negative women 30 years and older",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 629px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Test that detects any of the 14 high-risk (oncogenic) types of HPV.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: The ASCCP Clinical Update of March 19, 2009, with the permission of ASCCP &copy; 2004, 2009 American Society for Colposcopy and Cervical Pathology. No copies of the algorithms may be made without the prior consent of ASCCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34021=[""].join("\n");
var outline_f33_14_34021=null;
var title_f33_14_34022="Digitate dermatosis";
var content_f33_14_34022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digitate dermatosis (small plaque parapsoriasis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic finger-shaped, erythematous patches with an atrophic, cigarette-paper surface are present on the flanks of this patient with digitate dermatosis, a variant of small plaque parapsoriasis. Note the distribution of the lesions along the skin cleavage lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34022=[""].join("\n");
var outline_f33_14_34022=null;
var title_f33_14_34023="Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma";
var content_f33_14_34023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34023/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/14/34023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angioimmunoblastic T cell lymphoma (AITL) is one of the more common PTCLs and is thought to arise from peripheral CD4 positive T cells, corresponding to a subset of follicular helper T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Patients typically present with the acute onset of a systemic illness and lymph node biopsy demonstrates a polymorphous infiltrate with a prominent proliferation of high endothelial venules and follicular dendritic cells.",
"   </p>",
"   <p>",
"    In the past, AITL was thought to arise from an abnormal immune reaction characterized by an atypical lymphoid hyperplasia with immunoblastic and vascular proliferation, frequently accompanied by dysproteinemia. This was referred to as &ldquo;angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).&rdquo; It has since been realized that essentially all cases of AILD have rearrangements of the T cell receptor genes and thus represent a frank T cell lymphoma rather than a benign entity with high risk for transformation to one. The term AILD should probably no longer be used. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, and diagnosis of AITL will be discussed here. The other T cell lymphomas, including the",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell types, and the pathobiology and treatment of the PTCLs are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;AITL is one of the more common peripheral T cell lymphomas (PTCLs) encountered in Western countries. Incidence varies by geography with the highest rates in Europe (28 percent of PTCLs) and lower rates in North America (15 percent PTCLs) and Asia (17 percent PTCLs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In the United States the incidence is approximately 0.05 cases per 100,000 person years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AITL usually affects older adults with a median age of approximately 60 to 65 years (range 20 to 86 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Incidence appears to be approximately equal in men and women, although some reports have noted a slight male predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AITL typically present with the acute onset of a systemic illness. Less commonly, patients may present with asymptomatic lymphadenopathy.",
"   </p>",
"   <p>",
"    Symptoms frequently include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/13,15-19\">",
"     13,15-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized lymphadenopathy (76 to 95 percent)",
"     </li>",
"     <li>",
"      Hepatomegaly (50 to 70 percent)",
"     </li>",
"     <li>",
"      Splenomegaly (70 percent)",
"     </li>",
"     <li>",
"      Systemic B symptoms of fevers, night sweats, or weight loss (70 to 85 percent)",
"     </li>",
"     <li>",
"      Rash (20 to 60 percent)",
"     </li>",
"     <li>",
"      Polyarthritis (20 percent)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ascites/effusions",
"      </span>",
"      (20 to 35 percent)",
"     </li>",
"     <li>",
"      Symptoms related to anemia (20 to 50 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rash is usually pruritic and may demonstrate lymphohistiocytic vasculitis on biopsy. The vast majority (90 percent) of patients present with advanced (stage",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    disease. The bone marrow is involved in 30 to 60 percent of cases. While extranodal involvement is present in approximately one-quarter, it is uncommon for AITL to present at a single, isolated extranodal site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory abnormalities are common and include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/13,16-19\">",
"     13,16-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum lactate dehydrogenase (LDH) and the erythrocyte sedimentation rate (ESR) in approximately 70 and 45 percent of cases, respectively.",
"     </li>",
"     <li>",
"      Polyclonal hypergammaglobulinemia is seen in 30 to 80 percent, but some cases demonstrate hypogammaglobulinemia or a monoclonal gammopathy.",
"     </li>",
"     <li>",
"      Positive Coombs test, with or without hemolysis (up to 30 percent).",
"     </li>",
"     <li>",
"      Elevated beta-2 microglobulin (22 to 65 percent).",
"     </li>",
"     <li>",
"      Lymphopenia, anemia, and thrombocytopenia are seen in approximately 45 percent, 30 to 50 percent, and 20 to 25 percent, respectively. Hypereosinophilia is noted in 30 to 40 percent.",
"     </li>",
"     <li>",
"      Approximately half of patients demonstrate hypoalbuminemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunologic abnormalities are common and can include plasmacytosis, polyclonal hypergammaglobulinemia, and a positive Coombs' test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/20\">",
"     20",
"    </a>",
"    ]. AITL can be associated with autoimmune phenomena including hemolytic anemia, vasculitis, polyarthritis, rheumatoid arthritis, and thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. Cold agglutinins and cryoglobulins can also be seen. These autoimmune features are thought to stem from immune dysregulation of both B cells and T cells, which together result in immunodeficiency and risk of opportunistic infections both before and during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Growth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved lymph nodes demonstrate partial or complete effacement of the normal architecture by a predominantly paracortical infiltrate of atypical lymphoid and inflammatory cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/4\">",
"     4",
"    </a>",
"    ]. Follicles may be hyperplastic, depleted, or absent. Peripheral sinuses are typically open and even dilated, and the abnormal infiltrate usually does not extend beyond the capsule into perinodal tissue.",
"   </p>",
"   <p>",
"    There is prominent neovascularization with arborizing high endothelial venules (HEV), many of which show thickened or hyalinized walls (",
"    <a class=\"graphic graphic_picture graphicRef86422 \" href=\"mobipreview.htm?35/51/36666\">",
"     picture 1",
"    </a>",
"    ). This can be particularly well appreciated with a Periodic Acid Schiff (PAS) stain. Clusters of epithelioid histiocytes and numerous eosinophils and plasma cells may be present. Expanded aggregates of follicular dendritic cells, best appreciated in sections immunostained for dendritic cell markers, surround the proliferating blood vessels, and may have the appearance of \"burned-out\" germinal centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cell morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infiltrating lymphoid cells are a mixture of small lymphocytes, immunoblasts, polyclonal plasma cells, eosinophils, histiocytes, epithelioid cells, and medium-sized cells with round or irregular nuclei and moderately abundant clear cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef86423 \" href=\"mobipreview.htm?36/16/37129\">",
"     picture 2",
"    </a>",
"    ). In the past, this mixture of cells suggested a reactive process (angioimmunoblastic lymphadenopathy with dysproteinemia syndrome). As the lesion progresses, cells with clear cytoplasm increase in number and efface the lymph node. In most cases, these clear cells are closely associated and intermingled with the expanded follicular dendritic cell (FDC) network. B-immunoblasts may be numerous in areas between the FDCs and often harbor Epstein-Barr virus (EBV). The malignant T cells and the background reactive component most often fail to penetrate beyond the lymph node capsule, but infiltration into the perinodal fat is sometimes seen. B immunoblasts that are EBV positive are sometimes very prominent and occasionally give rise to secondary EBV positive diffuse large B cell lymphomas. Occasionally, binucleated or multinucleated cells that resemble the Reed-Sternberg (RS) cells of Hodgkin lymphoma may be observed. These RS-like cells are usually EBV-positive and may be akin to similar appearing cells that are found on occasion in lymph nodes of patients with infectious mononucleosis. The inflammatory background that is characteristic of true Hodgkin lymphoma is absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Bone marrow involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow involvement in AITL usually takes the form of paratrabecular and interstitial polymorphous infiltrates containing cytologically atypical lymphocytes mixed with histiocytes and eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/21\">",
"     21",
"    </a>",
"    ]. The lymphomatous infiltrate in some marrow specimens contains numerous small or scattered large B cells, resembling either benign lymphoid aggregates or T cell rich large B cell lymphoma. Secondary changes such as trilineage hyperplasia and polyclonal plasmacytosis are frequent and present independent of marrow involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;AITL tumor cells appear to be the malignant counterparts of an unusual subset of CD4-positive follicular T helper cells. The tumor cells express pan T cell antigens (ie, CD3, CD2, and CD5) and almost always CD4 (",
"    <a class=\"graphic graphic_picture graphicRef86424 \" href=\"mobipreview.htm?29/38/30314\">",
"     picture 3",
"    </a>",
"    ). Many reactive CD8 expressing T cells are often present; expanded follicular dendritic cell (FDC) networks that express CD21, CD23, and CD35 are usually present, often in areas where malignant T cells with abundant pale cytoplasm are seen (",
"    <a class=\"graphic graphic_picture graphicRef86425 \" href=\"mobipreview.htm?23/16/23818\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The latter feature is useful in distinguishing this disorder from other T cell lymphomas, which do not contain expanded populations of FDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The malignant T cells frequently express CD10, CXCL13, PD-1, and Bcl-6, markers that are expressed by normal follicular T helper cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/4,24,25\">",
"     4,24,25",
"    </a>",
"    ]. As an example, in one study, CD10 positive T cells were found in 27 of 30 cases of AITL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, no CD10 positive T cells were present in 10 cases of other peripheral T cell lymphomas or 10 cases of reactive lymphoid hyperplasia. Single cell studies indicated that the CD10 positive cells belonged to the neoplastic clone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor genes are rearranged in 75 to 90 percent; immunoglobulin heavy chains may be rearranged in 25 percent, corresponding to the secondarily expanded B cell clones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Epstein-Barr virus (EBV) and human herpes virus-6 (HHV6) genomes are detected in many cases and may be present in either T or B cells, although EBV is far more common in the B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many genetic abnormalities have been reported, but there is no single cytogenetic change that is typical or diagnostic of AITL. The most common genetic abnormalities seen are trisomy 3, trisomy 5,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an additional X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. There is also an unusually high incidence of subclones with distinct chromosomal aberrations; the mechanism underlying the apparent genomic instability is unknown. Gene expression profiling demonstrates a pattern similar to that expressed by follicular helper T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of AITL is best made by excisional tissue biopsy, most commonly a lymph node interpreted in the context of the clinical presentation. Lymph node evaluation includes assessment of the morphology and immunophenotyping, which are essential to make the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"mobipreview.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    ). In difficult cases, PCR-based tests to look for the presence of clonal T cell receptor rearrangements can be helpful.",
"   </p>",
"   <p>",
"    As described above, the histology reveals effaced nodal architecture, prominent arborizing high endothelial venules, and a polymorphous infiltrate including reactive lymphocytes, immunoblasts, plasma cells, inflammatory cells, and small to large atypical lymphocytes that are positive for CD3 and CD4. As with other peripheral T cell lymphomas, the tumor cells may lose a subset of pan-T cell markers and exhibit an aberrant immunophenotype. Follicular dendritic cells (FDCs) are inconspicuous histologically, but staining for markers such as CD21 usually demonstrates irregularly shaped expansions of these cells.",
"   </p>",
"   <p>",
"    When clusters of atypical T cells with abundant clear cytoplasm are present, they are typically found within the expanded FDC network. In most cases, Epstein-Barr virus (EBV) positive B immunoblasts, best detected by in situ hybridization for small nuclear EBV RNAS (EBERs), are present in areas between the FDCs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3114?source=see_link&amp;anchor=H17#H17\">",
"     \"Virology of Epstein-Barr virus\", section on 'EBER-1 and EBER-2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other peripheral T cell lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both AITL and other peripheral T cell lymphomas (PTCLs) typically express pan T cell associated antigens (ie, CD3, CD2, and CD5) and demonstrate T cell receptor gene rearrangements. AITL is distinguished from other PTCLs by expression of CD10, CXCL13 and PD-1 and the presence of expanded meshworks of follicular dendritic cells (FDCs) expressing CD21, CD23, and CD35. FDCs are not expanded in other PTCLs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, binucleated or multinucleated cells that resemble the Reed-Sternberg (R-S) cells of Hodgkin lymphoma (HL) may be observed in angioimmunoblastic T cell lymphoma. These cells can even exhibit the immunophenotypic characteristics of true R-S cells, making distinction from HL difficult. However, unlike in Hodgkin lymphoma, there will be a clonal T cell receptor gene rearrangement in most cases of AITL. The prominent vascular proliferation and the proliferation of atypical T cells with clear cytoplasm are absent in HL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1022779\">",
"    <span class=\"h2\">",
"     EBV-positive diffuse large B cell lymphoma of the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV-positive diffuse large B cell lymphoma of the elderly is a subtype of B cell lymphoma characterized by the presence of numerous large EBV+ B cells and that often involves extranodal sites. Vascular invasion by the tumor cells may produce tissue necrosis. The EBV+ B cells in AITL are usually scattered, but in instances where small biopsies are taken, EBV+ B cells (usually detected by in situ hybridization for EBV EBER RNAs) can be sufficiently numerous to cause diagnostic confusion. The keys to making the distinction are recognition of the underlying T cell proliferation and performance of gene rearrangements studies, which will show a polyclonal B cell population in AITL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link&amp;anchor=H2612844#H2612844\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'EBV-positive DLBCL of the elderly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of AITL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Angioimmunoblastic T cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AITL is generally an aggressive disease, although occasional spontaneous remissions are seen, and its course is not reliably predicted by the histologic appearance. In addition, prognostic models used for other types of non-Hodgkin lymphoma have limited applicability to patients with AITL. Most patients with AITL fall into the high-risk category when assessed with either the International Prognostic Index (IPI) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) or the similar Prognostic Index for T cell lymphomas (PIT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/15,25,31,32\">",
"     15,25,31,32",
"    </a>",
"    ]. Studies of gene expression profiling have suggested that overexpression of genes associated with proliferation was associated with shorter survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from the International Peripheral T cell Lymphoma Project of 243 patients with AITL, estimated rates of overall and failure-free survival at five years were 33 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of patients fell into high risk categories using the IPI (79 percent) and the PIT (63 percent), respectively. An alternative prognostic index for AITL (PIAI) was proposed that incorporated age, performance status, extranodal involvement, B symptoms, and thrombocytopenia. When applied to a validation cohort, the PIAI separated patients into low and high risk disease with significantly different estimated rates of overall (44 versus 24 months) and failure-free (28 versus 15 percent) survival at five years.",
"   </p>",
"   <p>",
"    A retrospective analysis from Japan of 207 patients with AITL with a median follow-up of 42 months reported three-year overall and progression-free survival rates of 54 and 38 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/34\">",
"     34",
"    </a>",
"    ]. Overall survival at three years according to IPI score was 81, 69, 53, and 35 percent for patients with low-, low-intermediate-, high-intermediate-, and high-risk IPI, respectively.",
"   </p>",
"   <p>",
"    Although complete remission can be attained in many patients, relapse is frequent. Infection is the most common cause of death. Up to a third of patients may be long-term survivors after treatment with chemotherapy with or without autologous hematopoietic cell transplantation. The treatment of AITL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients will develop a secondary B cell lymphoma, which is often, but not invariably, Epstein-Barr virus positive, and may be the result of ongoing somatic hypermutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34023/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29529?source=see_link&amp;anchor=H38689713#H38689713\">",
"     \"Overview of the pathobiology of the non-Hodgkin lymphomas\", section on 'B cell germinal center reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angioimmunoblastic T cell lymphoma (AITL) is one of the more common peripheral T cell lymphomas and is thought to arise from peripheral CD4 positive T cells, perhaps corresponding to a subset of follicular helper T cells.",
"     </li>",
"     <li>",
"      Patients typically present with the acute onset of a systemic illness characterized by generalized lymphadenopathy, hepatosplenomegaly, systemic B symptoms (ie, fever, night sweats, weight loss), with or without a rash. It can also be associated with immunologic abnormalities, such as autoimmune hemolytic anemia, plasmacytosis, or polyclonal hypergammaglobulinemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AITL is best made by excisional tissue biopsy, most commonly a lymph node interpreted in the context of the clinical presentation (",
"      <a class=\"graphic graphic_table graphicRef55385 \" href=\"mobipreview.htm?5/61/6109\">",
"       table 1",
"      </a>",
"      ). The histology reveals effaced nodal architecture, prominent arborizing high endothelial venules, and a polymorphous infiltrate including small to large atypical lymphocytes that are positive for CD3 and CD4. Expanded networks of follicular dendritic cells are demonstrated by staining for markers such as CD21. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/3\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/5\">",
"      Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/6\">",
"      Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 2005; 106:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/7\">",
"      Krenacs L, Schaerli P, Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood 2006; 108:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/8\">",
"      de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109:4952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/9\">",
"      Rudiger T, Weisenburger DD, Coiffier B, et al. Angioimmunoblastic T-cell Lymphoma: A report from the international peripheral T-cell lymphoma project. Ann Oncol 2008; 19(suppl 4):iv119.",
"     </a>",
"    </li>",
"    <li>",
"     Lennert K, Feller A. Histopathology of non-Hodgkin's lymphomas, Springer-Verlag, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/11\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/12\">",
"      Ohsaka A, Saito K, Sakai T, et al. Clinicopathologic and therapeutic aspects of angioimmunoblastic lymphadenopathy-related lesions. Cancer 1992; 69:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/13\">",
"      Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/14\">",
"      Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995; 6:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/15\">",
"      Federico M, Rudiger T, Bellei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013; 31:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/16\">",
"      Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004; 127:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/17\">",
"      Seehafer JR, Goldberg NC, Dicken CH, Su WP. Cutaneous manifestations of angioimmunoblastic lymphadenopathy. Arch Dermatol 1980; 116:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/18\">",
"      Park BB, Ryoo BY, Lee JH, et al. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007; 48:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/19\">",
"      Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003; 121:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/20\">",
"      Sallah S, Gagnon GA. Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. Acta Haematol 1998; 99:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/21\">",
"      Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 2007; 137:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/22\">",
"      Lee SS, R&uuml;diger T, Odenwald T, et al. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 2003; 103:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/23\">",
"      Feller AC, Griesser H, Schilling CV, et al. Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 1988; 133:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/24\">",
"      Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002; 99:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/25\">",
"      Mourad N, Mounier N, Bri&egrave;re J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008; 111:4463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/26\">",
"      Weiss LM, Strickler JG, Dorfman RF, et al. Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 1986; 122:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/27\">",
"      Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/28\">",
"      Weiss LM, Jaffe ES, Liu XF, et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/29\">",
"      Zhou Y, Attygalle AD, Chuang SS, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007; 138:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/30\">",
"      Schlegelberger B, Feller A, G&ouml;dde E, et al. Stepwise development of chromosomal abnormalities in angioimmunoblastic lymphadenopathy. Cancer Genet Cytogenet 1990; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/31\">",
"      A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/32\">",
"      Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/33\">",
"      Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007; 25:3321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/34\">",
"      Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 2012; 119:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34023/abstract/35\">",
"      Willenbrock K, Br&auml;uninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 2007; 138:733.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4727 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34023=[""].join("\n");
var outline_f33_14_34023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Growth pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cell morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Bone marrow involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other peripheral T cell lymphomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1022779\">",
"      EBV-positive diffuse large B cell lymphoma of the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4727|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/51/36666\" title=\"picture 1\">",
"      AITL arborizing blood vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/16/37129\" title=\"picture 2\">",
"      AITL high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/38/30314\" title=\"picture 3\">",
"      AITL CD3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/16/23818\" title=\"picture 4\">",
"      AITL CD21",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4727|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/61/6109\" title=\"table 1\">",
"      PTCL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29529?source=related_link\">",
"      Overview of the pathobiology of the non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_14_34024="Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients";
var content_f33_14_34024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Christine Johnston, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34024/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/14/34024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28740777\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital herpes simplex is a common sexually transmitted viral infection that is found worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/1\">",
"     1",
"    </a>",
"    ]. Most often genital herpes is secondary to herpes simplex virus type 2 (HSV-2), although about half of all new cases in developed countries are due to herpes simplex virus type 1 (HSV-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and related drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ) is rare in immunocompetent hosts, but is seen more commonly among immunocompromised hosts, including HIV-infected patients and transplant recipients. This topic will review therapeutic options and strategies for prevention for drug-resistant infection in the HIV-infected patient. The epidemiology, natural history, clinical manifestations, and treatment of drug-sensitive HSV infection in the HIV-infected host are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41799?source=see_link\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=see_link\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740792\">",
"    <span class=\"h1\">",
"     MECHANISMS OF DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    are antiviral agents within the nucleoside analog class. After intracellular uptake, acyclovir is converted to acyclovir monophosphate by virally-encoded thymidine kinase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/2\">",
"     2",
"    </a>",
"    ]. The monophosphate derivative is subsequently converted by cellular enzymes to acyclovir triphosphate, which is a specific inhibitor of HSV DNA polymerase. HSV drug resistance to acyclovir infers broad cross-resistance to this entire class of antiviral agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H2#H2\">",
"     \"Acyclovir: An overview\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three mechanisms have been found that result in resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced or absent thymidine kinase",
"     </li>",
"     <li>",
"      Altered thymidine kinase activity resulting in decreased",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      phosphorylation",
"     </li>",
"     <li>",
"      Altered viral DNA polymerase with decreased affinity for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      triphosphate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of isolates from a series of 12 AIDS patients with resistant HSV-2 indicated marked thymidine kinase deficiency in each case; these strains were cross-resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , which also requires phosphorylation for antiviral activity, but were sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , which acts by directly inhibiting DNA polymerase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28740862\">",
"     'Management of drug-resistant ulcerative disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740799\">",
"    <span class=\"h1\">",
"     PREVALENCE OF DRUG RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1908854\">",
"    <span class=\"h2\">",
"     Epidemiologic studies of drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    drug resistance is rare among immunocompetent persons; epidemiologic surveys have documented acyclovir-resistant virus in less than 1 percent of immunocompetent individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/6\">",
"     6",
"    </a>",
"    ]. Acyclovir drug resistance is more prevalent among immunocompromised patients, including HIV-infected hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In a study of 3602 patients seen in sexually transmitted disease (STD) clinics with genital ulcerative disease, 2088 had evidence of HSV-2 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/8\">",
"     8",
"    </a>",
"    ]. Laboratory testing demonstrated that 3 of 1644 (0.18 percent) HIV-seronegative patients had evidence of HSV-2 drug resistance compared with 12 of 226 (5.3 percent) HIV-seropositive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1908861\">",
"    <span class=\"h2\">",
"     Clinical importance of drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical importance of these epidemiologic findings is unclear since documentation of HSV-resistant strains from herpetic lesions does not necessarily predict failure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Most of these acyclovir-resistant viruses are TK-deficient strains, which appear less virulent in vitro than acyclovir-sensitive HSV. In addition, no person-to-person transmission of TK-deficient HSV stains has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/12\">",
"     12",
"    </a>",
"    ]. Rare reports of clinically important drug-resistant HSV disease have been documented in the immunocompetent host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/13\">",
"     13",
"    </a>",
"    ]; among normal hosts, TK-deficient strains usually spontaneously clear without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, clinical drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    has been occasionally reported in immunocompromised individuals. Some experts suggest that the risk of drug resistance is higher in these patients because antiviral drug exposure is often prolonged due to slower healing of ulcerative lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, the laboratory confirmation of acyclovir drug resistance is an important finding in a patient who has persistent or expanding HSV-related lesions, despite adequate antiviral therapy. Such a finding would support the need for alternative treatment, which is discussed below. (See",
"    <a class=\"local\" href=\"#H28740862\">",
"     'Management of drug-resistant ulcerative disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1909852\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients, risk factors for HSV drug resistance include a history of recurrent HSV infection, prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    exposure (particularly if the patient was treated with a suboptimal dose), history of a non-healing lesion, and low CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740813\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT HSV-RELATED DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-resistant infection should be suspected among patients with documented HSV who have minimal improvement, or an increase in lesion size, within 7 to 10 days of appropriately dosed antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Of note, recommended dosing and duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and related compounds for the treatment of genital HSV infection is generally higher in the HIV-infected patient compared with the HIV-uninfected patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41799?source=see_link&amp;anchor=H4856590#H4856590\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\", section on 'Dosing guidelines for antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unusual presentations of mucocutaneous HSV infection are more common in severely immunocompromised patients, such as AIDS patients or bone marrow transplant recipients. However, atypical manifestations of HSV infection do not necessarily infer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=see_link&amp;anchor=H11525287#H11525287\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740820\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance testing should only be performed in patients with clinical treatment failure in response to nucleoside analog therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Routine baseline testing of all patients for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    drug resistance is not recommended.",
"   </p>",
"   <p>",
"    A variety of methods have been used to determine drug susceptibility of HSV isolates to antiviral agents. The most widely recommended test is the plaque reduction assay: an IC50 &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    indicates that phenotypic resistance is present. This assay is preferred over other diagnostic tests, since a correlation has been established between in vitro",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    susceptibility and clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/4,20\">",
"     4,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, this test depends upon ability to culture the virus; thus, a sample for viral culture must be obtained. If there is any question regarding the underlying diagnosis, an additional sample can be obtained for polymerase chain reaction (PCR) testing, which is more sensitive than culture for documenting HSV infection. However, clinicians need to be aware that samples obtained for PCR testing cannot be used for resistance testing. Our institution sends samples to Viro-Med (1-800-582-0077) for the plaque reduction assay. Downsides of this assay include a long turn-around time (ie, 15 to 17 days). &nbsp;",
"   </p>",
"   <p>",
"    Ninetyfive percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resistant strains have mutations in the viral thymidine kinase gene; the remaining 5 percent of acyclovir resistance is due to mutations in the viral DNA polymerase gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/21\">",
"     21",
"    </a>",
"    ]. Sequencing of these genes for genotypic diagnosis of acyclovir resistance may be performed in research labs, but this is not yet available for routine clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/4\">",
"     4",
"    </a>",
"    ]. With increasing identification of thymidine kinase polymorphisms and mutants associated with acyclovir drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], there is hope that a molecular assay for resistance testing may be developed in the future. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1909244\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS FOR ACYCLOVIR-RESISTANT HSV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    drug resistance infers cross-resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ; there are no other oral therapeutic options to treat HSV. (See",
"    <a class=\"local\" href=\"#H28740792\">",
"     'Mechanisms of drug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Alternative intravenous and topical options include formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , which target the viral DNA polymerase enzyme instead of thymidine kinase; continuous high-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ; and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/23\">",
"     23",
"    </a>",
"    ]. Although vidarabine has activity against herpes viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/24\">",
"     24",
"    </a>",
"    ], it is not effective in patients with acyclovir resistance, as discussed below.",
"   </p>",
"   <p>",
"    Due to the toxicity of alternative therapies, it is recommended that an infectious disease physician co-manage patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant herpes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740848\">",
"    <span class=\"h2\">",
"     Foscarnet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited clinical data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV infection are available from the early 1990s prior to the availability of potent antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/15,25-27\">",
"     15,25-27",
"    </a>",
"    ]; however, this is the drug of choice for treatment of acyclovir-resistant herpes due to limited therapeutic options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 1991 clinical trial involving 25 AIDS patients (CD4 &lt;20",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant mucocutaneous HSV infection, 14 patients were randomly assigned to antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of body weight intravenously every eight hours) or vidarabine (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenous daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/15\">",
"     15",
"    </a>",
"    ]. Severe neurologic toxicity was observed in three of six patients who received vidarabine, and as a result the Data Safety Monitoring Board recommended that the trial be stopped.&nbsp;Eleven additional patients were treated with open label foscarnet. All isolates were susceptible to foscarnet and vidarabine in vitro. Therapy was given for 10 days if all lesions had healed, or up to 42 days for patients with a partial response. The median number of lesions per patient was similar in both treatment arms at baseline (n = 2).",
"   </p>",
"   <p>",
"    Lesions in the first eight patients assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    healed completely after 10 to 24 days of treatment. HSV lesions recurred in 17 of 25 patients within a median of 42 days of resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients who were retreated with foscarnet had clinical resolution of their recurrent ulcers. Of note, many of these viral isolates had improved in vitro sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    and its related compounds,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    is associated with significant toxicity. Adverse effects related to foscarnet include renal toxicity and electrolyte abnormalities, such as hypomagnesemia, hypocalcemia and hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/16\">",
"     16",
"    </a>",
"    ]. Patient monitoring is discussed below and elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44244?source=see_link&amp;anchor=H6#H6\">",
"     \"Foscarnet: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740855\">",
"    <span class=\"h2\">",
"     Topical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies have been used with some reported success for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resistant HSV genital lesions that are refractory to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or in patients that cannot tolerate foscarnet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/14,30\">",
"     14,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33539866\">",
"    <span class=\"h3\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    is a nucleotide analogue with in vitro activity against a broad range of herpesviruses, including thymidine-kinase deficient HSV-1 and HSV-2 isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/14\">",
"     14",
"    </a>",
"    ]. In a double-blind clinical trial, 30 AIDS patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV infection (median of two lesions at baseline) were randomly assigned to topical cidofovir gel or placebo gel for five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/14\">",
"     14",
"    </a>",
"    ]. Ten of 20 patients receiving cidofovir attained complete lesion resolution or 50 percent improvement in clinical symptoms compared with none of the patients receiving placebo. The median time for a clinical response to therapy was 21 days. Application site reactions occurred in 25 percent of cidofovir-treated patients and 20 percent of placebo-treated patients.",
"   </p>",
"   <p>",
"    The application of these data to clinical practice is mainly limited by the drug itself; topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    is not commercially available and must be compounded by the pharmacy. Thus, it is difficult to standardize dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/18\">",
"     18",
"    </a>",
"    ]. Information on the use of intravenous cidofovir is found below. (See",
"    <a class=\"local\" href=\"#H33539887\">",
"     'Intravenous cidofovir'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33539873\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports describe the successful use of intralesional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/31\">",
"     31",
"    </a>",
"    ] and topical 5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has also been used as a salvage therapy in severe cases of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant herpes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740862\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF DRUG-RESISTANT ULCERATIVE DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33539880\">",
"    <span class=\"h2\">",
"     Intravenous acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon clinical suspicion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV infection in patients receiving oral antiviral therapy, we suggest sending a culture for drug resistance testing and switching to intravenous acyclovir (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 8 hours), which achieves better serum concentrations than oral acyclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H5#H5\">",
"     \"Acyclovir: An overview\", section on 'Basic pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     US Food and Drug Administration&rsquo;s website",
"    </a>",
"    for information about the availability of IV acyclovir. If IV acyclovir is not available,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    can be used as discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1909392\">",
"    <span class=\"h2\">",
"     Intravenous foscarnet",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initiation of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , if there is no improvement in lesion size over approximately 5 to 10 days, or if the lesion progresses, the patient should be empirically treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously every eight hours) while awaiting results of drug resistance testing. Foscarnet should be continued for a minimum of three weeks or until healing of all mucocutaneous ulcers.",
"   </p>",
"   <p>",
"    During",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    therapy, patients should receive aggressive pre- and post-hydration to prevent nephrotoxicity and be carefully monitored twice weekly for electrolyte abnormalities, renal dysfunction, and bone marrow suppression. Elevations in creatinine can be seen within one to two weeks of foscarnet initiation. Concomitant nephrotoxic agents should be avoided, whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33539887\">",
"    <span class=\"h2\">",
"     Intravenous cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    may occur; intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg/week)",
"    </span>",
"    has been used with variable success in these cases, although there are limited data on the efficacy of intravenous cidofovir for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant HSV in the HIV-infected patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/40\">",
"     40",
"    </a>",
"    ] and only scant data are available in other immunocompromised hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among HIV-infected patients, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    has been used in HIV-infected patients with cytomegalovirus retinitis. However, intravenous administration of this drug is associated with severe toxicity, including neutropenia, nausea and vomiting, and nephrotoxicity; coadministration with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    and aggressive intravenous hydration (both pre- and post-dosing of cidofovir) are important adjunctive modalities to decrease the risk of adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1909462\">",
"    <span class=\"h2\">",
"     Patients with intolerance to foscarnet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options for the patient who is intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , or who has severe toxicity on therapy, are limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (30 to 45",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      has been successfully utilized for acyclovir-resistant herpes in other immunocompromised patient populations (ie, hematopoietic stem cell transplant recipients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/44\">",
"       44",
"      </a>",
"      ]. There are no data on this approach in HIV-infected patients.",
"     </li>",
"     <li>",
"      Topical therapies (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      ) may also be considered, although topical cidofovir requires compounding by the local pharmacy and, as noted above, the dosing is not standardized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28740890\">",
"    <span class=\"h1\">",
"     PATIENT MANAGEMENT AFTER RESOLUTION OF LESIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1235771\">",
"    <span class=\"h2\">",
"     Antiviral suppression of genital HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent drug-sensitive genital herpes can be usually managed with either chronic maintenance, or &ldquo;suppressive therapy&rdquo;, or with treatment of the episodes as they occur, known as &ldquo;episodic therapy&rdquo;.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    are all effective for reducing recurrences of HSV genital lesions among HIV-infected and HIV-seronegative patients with drug-sensitive infection. Of note, several of the recommended dosing regimens in the HIV-infected host are higher for acyclovir, famciclovir, and valacyclovir compared with the HIV-seronegative patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41799?source=see_link&amp;anchor=H251515427#H251515427\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\", section on 'Treatment strategies for recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike in many other infections, daily suppressive therapy with nucleoside analogues reduces, rather than increases, the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    resistance in immunocompromised patients. This concept was well illustrated in a retrospective study of three consecutive cohorts of hematopoietic stem-cell transplant recipients (n = 2049), which received acyclovir prophylaxis for varying durations of time after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/45\">",
"     45",
"    </a>",
"    ]. Cohort 1 received acyclovir for 30 days; cohort 2 received acyclovir for one year and cohort 3 received acyclovir for an extended period (greater than one year). The two-year probability of HSV disease was highest in the one-month prophylaxis group compared with the one-year and extended acyclovir prophylaxis groups (32 percent versus 4 percent and none, respectively). In addition, acyclovir-resistant disease developed in more patients in the one-month prophylaxis group compared with the other acyclovir groups (10 patients versus 2 patients and none, respectively).",
"   </p>",
"   <p>",
"    These data in an immunocompromised patient population suggest that long-term use of suppressive prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    may prevent the emergence of drug-resistant HSV disease. This point is critical, because withholding anti-HSV therapy to preserve future therapeutic options is more likely to lead to emergence of resistant virus compared with antiviral suppression of HSV reactivation.",
"   </p>",
"   <p>",
"    In patients who have a history of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant herpes, future HSV recurrences can be caused by either acyclovir-sensitive or acyclovir-resistant strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34024/abstract/15\">",
"     15",
"    </a>",
"    ]. Because the risk of HSV reactivation persists, we suggest that patients with a history of acyclovir-resistant herpes be maintained on daily suppressive antiviral therapy with acyclovir or a related agent. If herpetic ulcers recur, repeat resistance testing is recommended to determine whether acyclovir-resistant herpes persists. Dosing recommendations for suppressive therapy are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41799?source=see_link&amp;anchor=H4856617#H4856617\">",
"     \"Treatment of genital herpes simplex virus type 2 in HIV-infected patients\", section on 'Suppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1909886\">",
"    <span class=\"h2\">",
"     Optimization of HIV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to note that the clinical trials of HSV treatment in the patient with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    -resistant herpes infection were performed prior to the era of potent antiretroviral therapy (ART). Scrutiny of the patient&rsquo;s ART regimen, drug adherence, and drug-drug interactions is suggested to optimize CD4+ T-cell counts since the risk of drug-resistant herpes is related to immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28741555\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genital herpes simplex is a common sexually transmitted viral infection that is found worldwide. Manifestations of HSV infection among immunosuppressed patients may be characterized by genital ulcers that are more frequent, severe, and of longer duration than in immunocompetent patient populations. (See",
"      <a class=\"local\" href=\"#H28740777\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of drug resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , or related members of the nucleoside analog class, is increased among immunocompromised compared with immunocompetent patients. (See",
"      <a class=\"local\" href=\"#H28740799\">",
"       'Prevalence of drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risk factors for HSV drug resistance include a history of recurrent HSV infection, prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      exposure, a history of a non-healing lesion, advanced immunosuppression, and intermittent exposure to or suboptimal dosing of acyclovir. (See",
"      <a class=\"local\" href=\"#H1909852\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug resistance should be suspected in patients who do not have any improvement in lesion size after 7 to 14 days of antiviral therapy with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , or a related agent within this same class of drugs. A viral culture and a phenotypic assay for HSV drug resistance testing should be obtained and the patient should be switched to intravenous acyclovir (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours). Lesion progression, despite intravenous therapy, would be suggestive of drug resistance. Clinicians should also be certain that the appropriate dosing regimens are being used. (See",
"      <a class=\"local\" href=\"#H28740813\">",
"       'When to suspect HSV-related drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As of November 2012, there is a shortage of IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in the United States. If IV acyclovir is not available,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      can be used as discussed below. (See",
"      <a class=\"local\" href=\"#H33539880\">",
"       'Intravenous acyclovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every eight hours) for treatment of suspected or documented drug-resistant HSV-associated ulcerative disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Foscarnet should be continued until full lesion resolution. Patients should be carefully monitored for renal toxicity, bone marrow suppression and electrolyte abnormalities twice weekly. (See",
"      <a class=\"local\" href=\"#H28740862\">",
"       'Management of drug-resistant ulcerative disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have a history of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -resistant herpes, future HSV recurrences can be related to either acyclovir-sensitive or acyclovir-resistant strains. Daily suppressive therapy with nucleoside analogues reduces, rather than increases, the risk of acyclovir resistance in immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H28740862\">",
"       'Management of drug-resistant ulcerative disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the risk of HSV reactivation persists, we suggest that patients with a history of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      -resistant herpes be maintained on chronic suppressive antiviral therapy with acyclovir or a related agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Scrutiny of the patient&rsquo;s antiretroviral therapy regimen, drug adherence, and drug-drug interactions is suggested to optimize CD4+ T-cell counts since the risk of drug-resistant herpes is related to immunosuppression. (See",
"      <a class=\"local\" href=\"#H28740890\">",
"       'Patient management after resolution of lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/1\">",
"      Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/2\">",
"      Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/3\">",
"      Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/4\">",
"      Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/5\">",
"      Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/6\">",
"      Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998; 42:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/7\">",
"      Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis 2002; 186 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/8\">",
"      Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/9\">",
"      Str&aacute;nsk&aacute; R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/10\">",
"      Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/11\">",
"      Lehrman SN, Douglas JM, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 1986; 104:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/12\">",
"      Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993; Suppl 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/13\">",
"      Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/14\">",
"      Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/15\">",
"      Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325:551.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/17\">",
"      Cury K, Valin N, Gozlan J, et al. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient. Sex Transm Dis 2010; 37:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/18\">",
"      Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/19\">",
"      Gupta R, Wald A. Genital herpes: antiviral therapy for symptom relief and prevention of transmission. Expert Opin Pharmacother 2006; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/20\">",
"      Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994; 38:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/21\">",
"      Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/22\">",
"      Watson-Jones D, Wald A, Celum C, et al. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol 2010; 48:3496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/23\">",
"      Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med 1992; 92:3S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/24\">",
"      Whitley RJ, Gnann JW Jr, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis 1992; 165:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/25\">",
"      Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/26\">",
"      Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/27\">",
"      Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/28\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/29\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/30\">",
"      Lateef F, Don PC, Kaufmann M, et al. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998; 134:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/31\">",
"      Castelo-Soccio L, Bernardin R, Stern J, et al. Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir. Arch Dermatol 2010; 146:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/32\">",
"      Martinez V, Molina JM, Scieux C, et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2006; 119:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/33\">",
"      Abbo L, Vincek V, Dickinson G, et al. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Clin Infect Dis 2007; 44:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/34\">",
"      Danielsen AG, Petersen CS, Iversen J. Chronic erosive herpes simplex virus infection of the penis in a human immunodeficiency virus-positive man, treated with imiquimod and famciclovir. Br J Dermatol 2002; 147:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/35\">",
"      Holmes A, McMenamin M, Mulcahy F, Bergin C. Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals. Clin Infect Dis 2007; 44:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/36\">",
"      Verberkmoes A, Boer K, Wertheim PM, et al. Thalidomide for genital ulcer in HIV-positive woman. Lancet 1996; 347:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/37\">",
"      Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/40\">",
"      Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/41\">",
"      Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/42\">",
"      Andrei G, Fiten P, Goubau P, et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis 2007; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/43\">",
"      LoPresti AE, Levine JF, Munk GB, et al. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/44\">",
"      Kim JH, Schaenman JM, Ho DY, Brown JM. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biol Blood Marrow Transplant 2011; 17:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34024/abstract/45\">",
"      Erard V, Wald A, Corey L, et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196:266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16701 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34024=[""].join("\n");
var outline_f33_14_34024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28741555\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740777\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740792\">",
"      MECHANISMS OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740799\">",
"      PREVALENCE OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1908854\">",
"      Epidemiologic studies of drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1908861\">",
"      Clinical importance of drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1909852\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740813\">",
"      WHEN TO SUSPECT HSV-RELATED DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740820\">",
"      DIAGNOSIS OF DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1909244\">",
"      AVAILABLE AGENTS FOR ACYCLOVIR-RESISTANT HSV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28740848\">",
"      Foscarnet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28740855\">",
"      Topical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33539866\">",
"      - Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33539873\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740862\">",
"      MANAGEMENT OF DRUG-RESISTANT ULCERATIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33539880\">",
"      Intravenous acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1909392\">",
"      Intravenous foscarnet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33539887\">",
"      Intravenous cidofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1909462\">",
"      Patients with intolerance to foscarnet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28740890\">",
"      PATIENT MANAGEMENT AFTER RESOLUTION OF LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1235771\">",
"      Antiviral suppression of genital HSV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1909886\">",
"      Optimization of HIV therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28741555\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=related_link\">",
"      Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41799?source=related_link\">",
"      Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_14_34025="Microdeletion syndromes (chromosomes 1 to 11)";
var content_f33_14_34025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microdeletion syndromes (chromosomes 1 to 11)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Carlos A Bacino, MD, FACMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/14/34025/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/14/34025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2472601\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome deletions that span at least five megabases (Mb) are usually microscopically visible on chromosome banded karyotypes. Microdeletions, or submicroscopic deletions, are chromosomal deletions that are too small to be detected by light microscopy using conventional cytogenetic methods. Specialized testing is needed to identify these deletions. Microdeletions are typically one to three Mb long and involve several contiguous genes. The exact size and location of a microdeletion that causes a syndrome may vary, but a specific &ldquo;critical region&rdquo; is consistently involved. Most phenotypic effects of these microdeletions are due to haploinsufficiency of a few critical genes or in some cases a single gene.",
"   </p>",
"   <p>",
"    This topic reviews microdeletion syndromes involving chromosomes 1 through 11. Microdeletion syndromes involving chromosomes 12 through 22 are discussed separately, as are microduplication syndromes, and congenital abnormalities of the sex chromosomes. Other congenital chromosomal abnormalities, such as trisomies, are also reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37143?source=see_link\">",
"     \"Microduplication syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10024?source=see_link\">",
"     \"Sex chromosome abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4404114\">",
"    <span class=\"h1\">",
"     OVERVIEW OF GENOMIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic disorders are diseases that result from the loss or gain of",
"    <span class=\"nowrap\">",
"     chromosomal/DNA",
"    </span>",
"    material. The most common and better delineated genomic disorders are divided in two main categories, those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=see_link\">",
"     \"Genomic disorders: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Copy number variations (CNVs)",
"    <strong>",
"    </strong>",
"    are submicroscopic genomic differences in the number of copies of one or more sections of DNA that result in DNA gains or losses (",
"    <a class=\"graphic graphic_figure graphicRef67644 \" href=\"mobipreview.htm?40/28/41412\">",
"     figure 1",
"    </a>",
"    ). Some CNVs are pathogenic and cause syndromic disorders with consistent phenotypic features, as are discussed here. Other CNVs are associated with disease susceptibility or resistance and the same CNV can be associated with several diverse disorders. Still other CNVs are part of normal genetic variation and have no recognized disease association. Contiguous gene syndromes can occur when CNVs affect several adjacent genes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of genetic variation\", section on 'Copy number variations (CNVs)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=see_link&amp;anchor=H1031916#H1031916\">",
"     \"Basic principles of genetic disease\", section on 'Copy number variation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main mechanism that leads to disease in genomic disorders secondary to deletions and duplications is a change in the copy number of a dosage sensitive gene or genes. Other disease mechanisms include interference with imprinted genes and with regulatory elements outside genes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=see_link&amp;anchor=H16722227#H16722227\">",
"     \"Genomic disorders: An overview\", section on 'Disease mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genomic disorders are typically detected by array comparative genomic hybridization (array CGH) (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"mobipreview.htm?28/63/29687\">",
"     figure 2",
"    </a>",
"    ). Most laboratories confirm gains or losses detected on an array with an independent method such as fluorescent",
"    <em>",
"     in situ",
"    </em>",
"    hybridization (FISH), multiple ligation dependent probe amplification (MLPA), or quantitative PCR (Q-PCR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538652#H15538652\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Array comparative genomic hybridization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H627264199\">",
"    <span class=\"h1\">",
"     1p36 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome (MIM #607872), caused by a deletion with variable breakpoints at the distal tip of the short arm of chromosome 1, is one of the most common deletion syndromes. It is characterized by moderate to severe intellectual disabilities and craniofacial dysmorphisms, including microcephaly, brachycephaly, large and persistently open anterior fontanelle, deep set eyes, straight eyebrows, posteriorly rotated and low set ears, midface hypoplasia, flat nasal bridge, and pointy chin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Orofacial clefting can be seen in this deletion. In addition, these patients have hypotonia, congenital heart disease (some may develop noncompaction cardiomyopathy), renal anomalies, ophthalmologic abnormalities, skeletal anomalies, hearing loss, feeding difficulties, and hypothyroidism. Fifty percent develop seizures. Brain abnormalities are prevalent.",
"   </p>",
"   <p>",
"    Screening and monitoring studies include electroencephalogram (EEG) to check for seizures if suspected or as a baseline around one year of age, renal ultrasound upon diagnosis, annual thyroid function tests, echocardiogram upon diagnosis and subsequently every two to three years, swallowing evaluations, and auditory brainstem response hearing screening. Therapies essential to help with muscle tone and delays include physical, occupational, and speech therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86260767\">",
"    <span class=\"h1\">",
"     1q21.1 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This 1.35 Mb deletion is recurrent in size due to flanking segments that mediate these rearrangements. It is associated with microcephaly, intellectual disabilities (speech delay, learning disabilities), and mild dysmorphic facial features (MIM #612474) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, the presentation is variable given incomplete penetrance and variable expressivity, and the microdeletion is seen in unaffected carriers. Other findings can include more severe intellectual disabilities, seizures, cardiac abnormalities, and cataracts. Autism, ADHD, schizophrenia, and other psychiatric abnormalities have been reported.",
"   </p>",
"   <p>",
"    <em>",
"     HYDIN",
"    </em>",
"    is the key gene implicated in this disorder, since homozygous mutations in the paralog mouse gene cause hydrocephalus.",
"    <em>",
"     GJA5",
"    </em>",
"    and",
"    <em>",
"     GJA8",
"    </em>",
"    are the hypothesized genes responsible for the heart phenotype.",
"   </p>",
"   <p>",
"    Patients may require physical, occupational,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86260827\">",
"    <span class=\"h1\">",
"     DISTAL 1q21 DELETION SYNDROME (THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia-absent radius syndrome (TAR syndrome, MIM #274000) is characterized by hypomegakaryocytic thrombocytopenia and bilateral absent radii in the presence of thumbs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/11\">",
"     11",
"    </a>",
"    ]. Other skeletal abnormalities, as well as heart and genitourinary anomalies, may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=see_link&amp;anchor=H28#H28\">",
"     \"Neonatal thrombocytopenia\", section on 'Thrombocytopenia-absent radius syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology and inheritance is complex, although the syndrome is associated with a 1q21.1 deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This deletion extends approximately 200 kilobases (kb) containing 11 genes and is adjacent but distal (telomeric) to the deletion previously described on 1q21. The gene for RNA-binding motif protein 8A (",
"    <em>",
"     RBM8A",
"    </em>",
"    ) encodes the Y14 subunit of exon-junction complex that carries out crucial RNA processing tasks.",
"    <em>",
"     RBM8A",
"    </em>",
"    is located on 1q21.1 within the minimal deleted region in 1q21.1. Patients with TAR syndrome have been identified who have changes in this gene in addition to the 1q21.1 deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/14\">",
"     14",
"    </a>",
"    ]. This second change consists of a low frequency single nucleotide polymorphism (SNP) in the 5&prime; untranslated region (5&prime;UTR) of",
"    <em>",
"     RBM8A",
"    </em>",
"    or a novel SNP in the first intron of the same gene. These changes were found in 53 of 55 cases of patients with TAR syndrome in one series, with 51 also having the 1q21.1 deletion. This SNP appears to have regulatory properties and ultimately leads to a hypomorphic allele.",
"   </p>",
"   <p>",
"    Screening and monitoring studies include an echocardiogram to evaluate for congenital heart disease and close monitoring of platelet counts, particularly in the first weeks to months of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6403043\">",
"    <span class=\"h1\">",
"     2p15-16.1 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions of this region extend between 4 to 6 Mb. Clinical features include severe intellectual disability,",
"    <span class=\"nowrap\">",
"     autism/autistic",
"    </span>",
"    features, microcephaly, cortical",
"    <span class=\"nowrap\">",
"     dysplasia/pachygyria",
"    </span>",
"    on brain magnetic resonance imaging (MRI), renal abnormalities (multicystic kidneys, hydronephrosis), and camptodactyly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Craniofacial features are characteristic and include progressive microcephaly, flat occiput, small palpebral fissures, telecanthus, broad and high nasal root, long philtrum, rounded upper vermillion border, and everted lower lips. Two genes have been identified in the area as candidates for the autism component: exportin 1 (",
"    <em>",
"     XPO1",
"    </em>",
"    ) and orthodenticle homolog 1 (",
"    <em>",
"     OTX1",
"    </em>",
"    ).",
"   </p>",
"   <p>",
"    Screening for these patients includes a neurodevelopmental and autism evaluation, brain imaging studies, and a renal ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6403059\">",
"    <span class=\"h1\">",
"     2q23.1 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions of 2q23.1 have been seen in association with severe intellectual disability, seizures, autism spectrum disorder, short stature, and microcephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The severity of the seizures and the phenotype has led to initial diagnoses of Rett, Angelman, or Smith-Magenis syndrome.",
"    <em>",
"     MBD5",
"    </em>",
"    , a gene involved in the deleted region, belongs to the methyl CpG binding protein domain family that also includes the",
"    <em>",
"     MECP2",
"    </em>",
"    gene mutated in Rett syndrome.",
"    <em>",
"     MBD5",
"    </em>",
"    has also been implicated in autism. Other clinical findings include coarse facial features, abnormal sleep patterns, and behavioral problems.",
"   </p>",
"   <p>",
"    Screening for these patients include neurodevelopmental and autism evaluations, neurology evaluations with brain imaging studies, and EEG&rsquo;s.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86260896\">",
"    <span class=\"h1\">",
"     2q37 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This deletion (MIM #600430) is often referred to as Albright hereditary osteodystrophy-like syndrome. This is due to the fact that patients with distal 2q deletions present with mild to moderate intellectual disabilities, hypotonia, obesity, short stature, and brachydactyly with short phalanges (especially the third to fifth phalanges [brachydactyly type E]), as seen in patients with Albright syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/19\">",
"     19",
"    </a>",
"    ]. Dysmorphic features include thin, highly arched eyebrows, prominent forehead, depressed nasal bridge, full cheeks, hypoplastic alae nasi, prominent nasal septum, thin upper lip, and ear anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Autism is commonly reported in this deletion. Less common features include congenital heart disease (septal defects, aortic coarctation), gastrointestinal anomalies (pyloric stenosis, duodenal atresia), and central nervous system (CNS) anomalies.",
"   </p>",
"   <p>",
"    The main candidate gene for the brachymetaphalangism seen in this deletion syndrome is histone deacetylase 4",
"    <em>",
"     (HDAC4)",
"    </em>",
"    . Mice with deletions of the homologous gene",
"    <span class=\"nowrap\">",
"     Hdac4(-/-)",
"    </span>",
"    have severe bone malformations resulting from premature ossification of developing bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The obesity and intellectual disabilities may involve glypican 1 (",
"    <em>",
"     GPC1",
"    </em>",
"    ), G protein-coupled receptor 35 (",
"    <em>",
"     GPR35",
"    </em>",
"    ), and",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    protein kinase 25 (",
"    <em>",
"     STK25",
"    </em>",
"    ). The proposed genes for autism are gamma-2 centaurin (",
"    <em>",
"     CENTG2",
"    </em>",
"    ) and serotonin receptor 2B (",
"    <em>",
"     HTR2B",
"    </em>",
"    ).",
"   </p>",
"   <p>",
"    Screening studies include neurodevelopmental and autism evaluations, skeletal survey, endocrine evaluation, and an echocardiogram. Patients usually require physical, occupational, and speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12329301\">",
"    <span class=\"h1\">",
"     3p DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of the distal short arm of chromosome 3 (MIM #613792) is characterized by low birth weight, growth deficiency, intellectual disability, microcephaly, ptosis, telecanthus, downslanting palpebral fissures, micrognathia, postaxial polydactyly, and renal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Congenital heart defects (typically atrioventricular [AV] canal) occur in one-third of patients. Sensorineural hearing loss is frequently reported. The critical region for the deletion is located at 3p25 to 3p26. The deletion develops",
"    <em>",
"     de novo",
"    </em>",
"    in almost all cases. Haploinsufficiency of",
"    <em>",
"     CNTN4",
"    </em>",
"    (contactin 4), a brain expressed gene, may play a key role in these patients&rsquo; intellectual disability and autistic characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening of these patients includes echocardiogram at the time of diagnosis, renal ultrasound, hearing evaluations, neurodevelopmental, and autism evaluations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86260980\">",
"    <span class=\"h1\">",
"     3q29 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with this recurrent deletion (MIM #609425) have variable clinical findings despite the fact that the size of the deletion is almost identical (approximately 1.5 to 1.6 Mb) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The deletion encompasses 22 genes, although",
"    <em>",
"     PAK3",
"    </em>",
"    and",
"    <em>",
"     DPG2",
"    </em>",
"    are candidates for the critical genes responsible for the phenotype. These genes are homologues of known X-linked genes associated with intellectual disabilities. The clinical features include mild to moderate intellectual disability, microcephaly (50 percent of cases), and mild dysmorphisms including a narrow face, large ears, short philtrum, and a high nasal bridge. Patients with this deletion may have autism and ataxia. Less frequent features include chest wall deformities, cleft",
"    <span class=\"nowrap\">",
"     lip/palate,",
"    </span>",
"    long tapered fingers, ligamentous joint laity, horseshoe kidneys, and hypospadias.",
"   </p>",
"   <p>",
"    Screening studies include brain imaging studies, renal ultrasound, and neurodevelopmental and autism evaluations. Patients may require physical, occupational,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12329430\">",
"    <span class=\"h1\">",
"     4p DELETION SYNDROME (WOLF-HIRSCHHORN SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome (MIM #194190) is due to partial deletion of the short arm of chromosome 4 at 4p16.3. The deletion occurs de novo in approximately 87 percent of cases (about 80 percent involve the paternal chromosome), and in the remainder of the cases is due to a balanced translocation in one of the parents (most involve the maternal chromosome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The critical region for this syndrome has been narrowed to an approximately 200 kb region that includes the",
"    <em>",
"     WHSCR1",
"    </em>",
"    and",
"    <em>",
"     WHSCR2",
"    </em>",
"    genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/34\">",
"     34",
"    </a>",
"    ]. Wolf-Hirschhorn syndrome candidate 1 (",
"    <em>",
"     WHSC1",
"    </em>",
"    ) gene is deleted in all known cases of WHS. This gene encodes an H3K36me3-specific histone methyltransferase (HMTase) that plays a role in transcriptional regulation. One of the factors that WHSC1 modulates is Nkx2-5, a central transcriptional regulator of cardiac development. The interaction of WHSC1 with multiple different transcription factors may account for the variability in clinical phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/35\">",
"     35",
"    </a>",
"    ]. Some patients have larger deletions that can be visually identified in karyotypes, while others have microdeletions. There is some correlation between deletion size and clinical severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common clinical manifestations include pre- and postnatal growth restriction, microcephaly, congenital heart disease (atrial septal defect [ASD], ventricular septal defect [VSD], pulmonic stenosis [PS]), distinctive facial features with a &ldquo;Greek warrior helmet&rdquo; appearance of the nose due to high forehead, prominence of the glabella, hypertelorism, high and arched eyebrows, epicanthal folds, and downturned corners of the mouth. All of these patients have significant intellectual disabilities.",
"   </p>",
"   <p>",
"    Patients have frequent episodes of respiratory infections, due in part to recurrent aspiration. Antibody deficiencies are also common. In one series of 190 patients with WHS, immune defects occurred in about 4 percent of patients and included common variable immunodeficiency, IgA and IgG2 subclass deficiency, and impaired polysaccharide responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/37\">",
"     37",
"    </a>",
"    ]. T cell immunity is normal. Immunodeficiency does not appear to correlate with deletion size. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=see_link&amp;anchor=H21#H21\">",
"     \"Syndromic immunodeficiencies\", section on 'Partial deletions of chromosome 4p (Wolf-Hirschhorn syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening studies include neurodevelopmental evaluation and appropriate interventions. Feeding difficulties are common, therefore swallow studies are warranted. In some instances, the placement of a gastrostomy tube may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/38\">",
"     38",
"    </a>",
"    ]. Cardiac evaluations should be done by echocardiography. Screening of immunoglobulin subclasses in serum is recommended to assess for humoral deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12329086\">",
"    <span class=\"h1\">",
"     5q35 DELETION SYNDROME (SOTOS SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sotos syndrome (MIM #117550), also known as cerebral gigantism, is caused by haploinsufficiency of the",
"    <em>",
"     NSD1",
"    </em>",
"    gene located at 5q35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/39\">",
"     39",
"    </a>",
"    ]. Deletions in the chromosomal region containing",
"    <em>",
"     NSD1",
"    </em>",
"    are the most common cause of Sotos syndrome in the Japanese population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/40\">",
"     40",
"    </a>",
"    ], whereas point mutations of the",
"    <em>",
"     NSD1",
"    </em>",
"    gene are the most common cause in Caucasian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, Sotos syndrome is characterized by overgrowth that is evident at birth with an increase in head circumference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Hypotonia and delayed gross and fine motor milestones are typical. Often times these children are considered &ldquo;clumsy&rdquo;. They have mild intellectual disabilities. Patients with Sotos syndrome have characteristic facial features, with a bossed forehead, receding hairline, hypertelorism, downslanting palpebral fissures, large ears, high arched palate, and pointy chin. Premature teeth eruption is commonly seen. Skeletal features include scoliosis and large hands and feet. Advanced bone age is commonly seen. Brain imaging may show dilated ventricles, increased extra-axial cerebrospinal fluid (CSF), cortical atrophy spaces, and abnormalities of the corpus callosum. Cardiac anomalies, including patent ductus arteriosus (PDA) and atrial septal defect (ASD), are frequent in patients with 5q35 deletion. Renal anomalies may include hypoplastic kidneys and hydronephrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=see_link&amp;anchor=H8#H8\">",
"     \"The child with tall stature or abnormally rapid growth\", section on 'Cerebral gigantism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <em>",
"     NKX2.5",
"    </em>",
"    gene is also located in this deletion region. This gene is associated with congenital heart disease and atrioventricular conduction defects.",
"   </p>",
"   <p>",
"    Array CGH is the first line of testing if the diagnosis is suspected, followed by mutation studies if negative. Screening and monitoring studies include brain imaging, renal ultrasound, echocardiogram, and bone age. Therapy is supportive and includes referral to physical and occupational therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86261072\">",
"    <span class=\"h1\">",
"     6p25 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microdeletion of distal 6p (MIM #612582) is associated with a distinctive clinical phenotype including eye abnormalities (anterior chamber dysgenesis), hearing loss, congenital heart disease, dental anomalies, developmental delay, and a characteristic facial appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The facial features include a prominent forehead with turricephalic appearance, midface hypoplasia, downslanting palpebral fissures, hypertelorism, epicanthal folds, ptosis, proptosis, ear anomalies, flat nasal bridge, short",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smooth philtrum, and high palate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/48\">",
"     48",
"    </a>",
"    ]. Central nervous system (CNS) malformations are common, including hydrocephalus (ventriculomegaly), hypoplasia of the cerebellum (Dandy-Walker malformation), and brainstem and corpus callosum anomalies. Mild to moderate developmental delay is part of the syndrome. Other white matter abnormalities have been seen as part of this deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/49\">",
"     49",
"    </a>",
"    ]. Lastly heart defects (ventricular septal defect",
"    <span class=\"nowrap\">",
"     [VSD]/atrial",
"    </span>",
"    septal defect [ASD], patent foramen ovale [PFO], and patent ductus arteriosus [PDA]) have been reported.",
"   </p>",
"   <p>",
"    The eye malformations seen are known as the Axenfeld&ndash;Rieger malformation and include corneal opacities,",
"    <sup>",
"    </sup>",
"    iris coloboma, and hypoplasia of the iris with adherent iris",
"    <sup>",
"    </sup>",
"    strands to the peripheral cornea. The patient is considered to have Rieger anomaly if the iris demonstrates stromal hypoplasia, the pupils are distorted, or there are extra holes in the iris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/50\">",
"     50",
"    </a>",
"    ]. The iris is normal in patients who only have the Axenfeld anomaly.",
"   </p>",
"   <p>",
"    Posterior embryotoxon is a term used to describe a prominent and anteriorly displaced Schwalbe line (the anatomic line demarcating the outer limit of the corneal endothelium layer) that is seen in patients with the Axenfeld&ndash;Rieger malformation. Half of the patients with posterior embryotoxon will go on to develop glaucoma. Mutations in the human homologue of FoxC1 (mice) known as the forkhead transcription factor gene",
"    <em>",
"     FKHL7",
"    </em>",
"    cause an autosomal dominant form of glaucoma and are probably responsible for the glaucoma phenotype seen in this deletion syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"    <em>",
"     FOXC1",
"    </em>",
"    ,",
"    <em>",
"     FOXF2,",
"    </em>",
"    and",
"    <em>",
"     FOXQ1",
"    </em>",
"    that are part of the forkhead family of genes are involved in the deletion and also appear to play a significant role in this disorder.",
"   </p>",
"   <p>",
"    Careful ophthalmologic evaluations are needed, especially for patients with posterior embryotoxon given their increased risk for glaucoma. Other screening and monitoring studies include an echocardiogram, brain imaging studies, audiology evaluations including auditory brainstem response (ABR) testing and neurodevelopmental evaluation. Patients typically benefit from physical, occupational, and speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12329278\">",
"    <span class=\"h1\">",
"     7q11.23 DELETION SYNDROME (WILLIAMS SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome, also known as Williams-Beuren syndrome (WBS, MIM #194050), results from a heterozygous deletion of approximately 1.6 Mb at 7q11.23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The deletion includes the elastin gene",
"    <em>",
"     ELN",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/55\">",
"     55",
"    </a>",
"    ]. Cardiovascular abnormalities are frequent and are related to elastin haploinsufficiency. These abnormalities include supravalvular aortic stenosis (in 70 percent of cases), pulmonic valve stenosis, and renal artery stenosis. Renal abnormalities are also seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=see_link\">",
"     \"Williams-Beuren syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical features include constipation, which is often significant and is associated with an increased risk for diverticulosis and diverticulitis, failure to thrive, and sensorineural or conductive hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/53,54,56,57\">",
"     53,54,56,57",
"    </a>",
"    ]. Classical facial features include periorbital fullness of subcutaneous tissues, hypertelorism, stellate pattern of the iris, long philtrum, thick vermillion border of the lips, wide mouth, and small jaw (often referred to as elfin facies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Idiopathic hypercalcemia is observed and is frequently transient.",
"   </p>",
"   <p>",
"    Mild to moderate intellectual disability is common, with uneven cognitive disabilities. Verbal and memory performance is less impaired than visual-spatial perception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/58\">",
"     58",
"    </a>",
"    ]. Young patients with WBS tend to be very social, gregarious, and often overly friendly with strangers. Haploinsufficiency of the",
"    <em>",
"     GTF2I",
"    </em>",
"    gene appears to lead to the increased social interactions seen in patients with WBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/59\">",
"     59",
"    </a>",
"    ]. Behavioral abnormalities include anxiety and attention deficit disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening of these patients should include echocardiography, renal ultrasound with special attention to the renal artery, serum calcium, neurodevelopmental evaluations, and audiology evaluations including ABR testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86261212\">",
"    <span class=\"h1\">",
"     8q22.1 DELETION SYNDROME (NABLUS MASK-LIKE FACIAL SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions in the 8q21.3-q22.1 region that include a 2.79 Mb region at 8q22.1 are associated with the Nablus mask-like facial syndrome (MIM #608156) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. This rare condition has a striking phenotype that is characterized by severe blepharophimosis (bilateral ptosis with reduced lid size); glistening, tight-appearing facial skin; sparse and unruly hair; a flat and broad nose; and ears that are small and triangular in shape with prominent antihelices and unfolded helices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/63\">",
"     63",
"    </a>",
"    ]. Other anomalies include acquired microcephaly and submucous cleft palate. Hand anomalies include contractures and interdigital webbing. Developmental delay is also reported.",
"   </p>",
"   <p>",
"    A smaller deletion (1.6 Mb) in the 8q22.1 region was associated with speech delay and autism-spectrum disorder, but not the other features noted with the larger deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients will need ophthalmologic and plastic surgery evaluations for the surgical correction of blepharophimosis. In addition, patients with speech",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swallowing abnormalities should be evaluated for submucous cleft palate. Developmental evaluations and referral for physical, occupational,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy may also be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2473563\">",
"    <span class=\"h1\">",
"     8q24.11 DELETION SYNDROME (LANGER-GIEDION SYNDROME OR TRICHORHINOPHALANGEAL SYNDROME TYPE II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with this syndrome (MIM #105230) present with multiple dysmorphic facial features including large, laterally protruding ears, a bulbous nose, and an elongated upper lip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Additional clinical features include sparse scalp hair, winged scapulae, multiple cartilaginous exostoses, redundant skin, and intellectual disabilities. Skeletal findings also include cone epiphyses that are easily detected by hand radiographs. Tibial hemimelia has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 8q24.11 deletion involves",
"    <em>",
"     EXT1",
"    </em>",
"    (multiple exostoses type I gene, MIM #133700), the gene responsible for the exostoses.",
"   </p>",
"   <p>",
"    Trichorhinophalangeal syndrome type I (TRPS type I) is an autosomal dominant disorder with similar findings to TRPS type II, including the facial and skeletal findings (cone epiphyses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/70\">",
"     70",
"    </a>",
"    ]. However, patients with type I do not have intellectual disabilities or exostoses. TRPS type I is caused by mutations in",
"    <em>",
"     TRPS1",
"    </em>",
"    gene located in the 8q24.1 region, therefore haploinsufficiency of TRPS is directly related to most of the clinical features seen in this disorder.",
"   </p>",
"   <p>",
"    Skeletal surveys are performed to assess for exostoses and bone deformities. Patients may require developmental evaluations and referral to physical, occupational,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6403159\">",
"    <span class=\"h1\">",
"     9p22 DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of this syndrome consist of intellectual disability, trigonocephaly, midface hypoplasia, upward-slanting palpebral fissures, short nose with depressed nasal bridge, long philtrum, and micrognathia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these cases are due to a de novo deletion of the distal portion of the short arm of chromosome 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. The deletion occurs with similar frequency among chromosomes of paternal and maternal origin, therefore, genomic imprinting does not seem to play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/73\">",
"     73",
"    </a>",
"    ]. The critical region for the 9p deletion syndrome maps to a 4 to 6 Mb region in 9p22-9p23.",
"   </p>",
"   <p>",
"    Screening for these patients should include neurodevelopmental evaluations, echocardiogram to assess structural heart defects, and referral to a craniofacial surgeon to address trigonocephaly when present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86261300\">",
"    <span class=\"h1\">",
"     9q34.3 DELETION SYNDROME OR 9q SUBTELOMERE DELETION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome, also called Kleefstra syndrome (MIM #610253), is characterized by moderate to severe intellectual disability, microcephaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brachycephaly, hypertelorism, synophrys (joined eyebrows)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arched eyebrows, midface hypoplasia, a short nose with upturned nares, a protruding tongue with everted lower lip, and downturned corners of the mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with this deletion often have congenital heart defects (primarily atrial septal defect [ASD] or ventricular septal defect [VSD], tetralogy of Fallot, aortic coarctation, bicuspid aortic valve, and pulmonic stenosis). About half of patients have seizures (tonic-clonic, absence, complex partial seizures, and generalized seizure with focal onset). Behavioral abnormalities include maladaptive behaviors (aggression, hyperactivity, self-mutilation) and autistic spectrum features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/77\">",
"     77",
"    </a>",
"    ]. Sleep disturbances are reported and can be severe. Other features include major and minor eye, ear, genital, and limb anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 9q34.3 deletion syndrome is caused by haploinsufficiency of the",
"    <em>",
"     EHMT1",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/79\">",
"     79",
"    </a>",
"    ]. The product of this gene is a histone H3 Lys 9 (H3-K9) methyltransferase involved in histone methylation. Most patients with Kleefstra syndrome have this microdeletion, but some have mutations of the",
"    <em>",
"     EHMT1",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/80\">",
"     80",
"    </a>",
"    ]. The loss of other genes in the same region may cause additional clinical manifestations. The deletion of the distal long arm of chromosome 9 can be detected with subtelomeric FISH or array CGH.",
"   </p>",
"   <p>",
"    Screening studies include",
"    <span class=\"nowrap\">",
"     developmental/autism",
"    </span>",
"    evaluations, ophthalmologic evaluations, echocardiogram (ECG), and electroencephalogram (EEG). Patients require physical, occupational,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86261405\">",
"    <span class=\"h1\">",
"     10p14-p13 DELETION (DiGEORGE SYNDROME TYPE II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second locus for DiGeorge syndrome was recognized in patients with 10p deletions that presented with conotruncal heart defects, hypoparathyroidism, and T cell immunodeficiency (MIM #146255) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. These patients also have sensorineural hearing loss, which is not typically present in patients with DGS Type I (22q11.2 deletion).",
"    <em>",
"     GATA3",
"    </em>",
"    , the critical gene for this disorder, is essential for development of the parathyroid gland, auditory system, and kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=see_link&amp;anchor=H6#H6\">",
"     \"DiGeorge syndrome: Epidemiology and pathogenesis\", section on 'Other defects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with this deletion should have hearing evaluations and renal ultrasound, in addition to the usual screening studies in patients with DiGeorge syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15608?source=see_link\">",
"     \"DiGeorge syndrome: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2473577\">",
"    <span class=\"h1\">",
"     11p13 DELETION SYNDROME (WAGR SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;WAGR is an acronym that defines a sequence of abnormalities that include",
"    <strong>",
"     W",
"    </strong>",
"    ilms tumor,",
"    <strong>",
"     A",
"    </strong>",
"    niridia,",
"    <strong>",
"     G",
"    </strong>",
"    enitourinary anomalies, and mental",
"    <strong>",
"     R",
"    </strong>",
"    etardation (MIM #194072). Ophthalmologic findings include aniridia, cataracts, glaucoma, and nystagmus. The most common abnormalities of the genitourinary tract are cryptorchidism in males and streak ovaries and bicornuate uterus in females. Ambiguous genitalia have been reported in males and females. WAGR syndrome and Wilms tumor are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=see_link&amp;anchor=H4#H4\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\", section on 'WAGR syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    WAGR syndrome is a contiguous gene deletion syndrome. Deletions of",
"    <em>",
"     WT1",
"    </em>",
"    are responsible for Wilms tumor, while",
"    <em>",
"     PAX6",
"    </em>",
"    deletions are responsible for aniridia.",
"    <em>",
"     PAX6",
"    </em>",
"    and",
"    <em>",
"     WT1",
"    </em>",
"    are proximally located within 11p13. There is a different entity known as Denys-Drash syndrome (renal nephropathy, gonadal anomaly, predisposition to Wilms tumor) that is associated with",
"    <em>",
"     WT1",
"    </em>",
"    mutations. In addition, there are reports of larger deletions combining WAGR and Potocki-Shaffer syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86261562\">",
"    <span class=\"h1\">",
"     11p11.2 DELETION SYNDROME (POTOCKI-SHAFFER SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a contiguous gene deletion syndrome characterized by the presence of parietal foramina, abnormal craniofacial features, moderate to severe developmental delay, and exostoses (MIM #601224) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The parietal foramina appear related to deletions in",
"    <em>",
"     ALX4",
"    </em>",
"    and the exostoses are secondary to deletions of",
"    <em>",
"     EXT2",
"    </em>",
"    (exostosis Type II) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Studies of translocations in this region suggest that the intellectual disability and craniofacial anomalies seen in this syndrome are due to haploinsufficiency of",
"    <em>",
"     PHF21A",
"    </em>",
"    , a protein involved in histone methylation that mediates repression of neuron-specific genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening studies include a skeletal survey, magnetic resonance imaging (MRI) of the brain, renal ultrasound, and laboratory studies including a complete blood count, comprehensive metabolic panel, thyroid studies, and urinalysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2473584\">",
"    <span class=\"h1\">",
"     11q24.1 DELETION SYNDROME (JACOBSEN SYNDROME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal deletions of the long arm of chromosome 11 are associated with a condition known as Jacobsen syndrome (MIM #147791). More than 90 percent of these patients have Paris-Trousseau syndrome characterized by thrombocytopenia and platelet dysfunction that typically normalizes over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. More than half have serious congenital heart defects, including hypoplastic left heart syndrome, coarctation of the aorta, type B truncus arteriosus, and double outlet right ventricle. Recurrent infections of the upper respiratory system are common. Short stature and IGF-1 deficiency are also frequently seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=see_link\">",
"     \"Hypoplastic left heart syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients have dysmorphic craniofacial features including hypertelorism, downslanting palpebral fissures, ptosis, sparse eyebrows, broad nasal bridge with short nose and anteverted nares, thin upper lip, V-shaped mouth, and high arched palate. Other abnormalities include structural renal defects (duplicated ureters, single kidney, and hydronephrosis), genitourinary anomalies (undescended testes, hypospadias), and gastrointestinal anomalies (pyloric stenosis, constipation). Limb anomalies include syndactyly of hands and feet, fifth digit clinodactyly, and toe anomalies.",
"   </p>",
"   <p>",
"    Cognitive function ranges from normal intelligence to moderate intellectual disability. Nearly half of the patients have mild mental retardation with a characteristic neuropsychiatric profile demonstrating near normal receptive language ability, but mild to moderate impairment in expressive language.",
"   </p>",
"   <p>",
"    This syndrome can sometimes be diagnosed with conventional cytogenetic studies. Use of array CGH has redefined the phenotype and narrowed the critical region. Deletion of at least three out of the four platelet function critical genes that reside in the area,",
"    <em>",
"     ETS-1, FLI-1, NFRKB",
"    </em>",
"    , and",
"    <em>",
"     JAM3",
"    </em>",
"    , are apparently needed to develop thrombocytopenia, and deletions of",
"    <em>",
"     KCNJ1",
"    </em>",
"    and",
"    <em>",
"     ADAMTS15",
"    </em>",
"    may contribute to the renal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/14/34025/abstract/96\">",
"     96",
"    </a>",
"    ]. The heart genes are not yet identified.",
"   </p>",
"   <p>",
"    Screening studies include an echocardiogram, renal ultrasound, neurodevelopmental evaluations, and monitoring of platelet and coagulation function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86271084\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microdeletions, or submicroscopic deletions, are chromosomal deletions that are too small to be detected by light microscopy using conventional cytogenetics methods. (See",
"      <a class=\"local\" href=\"#H2472601\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genomic disorders are diseases that result from the loss or gain of",
"      <span class=\"nowrap\">",
"       chromosomal/DNA",
"      </span>",
"      material. The most common and better delineated genomic disorders are divided in two main categories, those resulting from copy number losses (deletion syndromes) and copy number gains (duplication syndromes). (See",
"      <a class=\"local\" href=\"#H4404114\">",
"       'Overview of genomic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      1p36 deletion syndrome (MIM #607872) is one of the most common microdeletion syndromes. It is characterized by moderate to severe intellectual disabilities and craniofacial dysmorphisms. In addition, these patients have hypotonia, congenital heart disease, renal and skeletal anomalies, ophthalmologic abnormalities, hearing loss, feeding difficulties, and hypothyroidism. Brain abnormalities and seizures may also occur. (See",
"      <a class=\"local\" href=\"#H627264199\">",
"       '1p36 deletion syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      4p deletion syndrome (Wolf-Hirschhorn syndrome, MIM #194190) is characterized by pre- and postnatal growth restriction, microcephaly, congenital heart disease, significant intellectual disabilities, and distinctive facial features with a &ldquo;Greek warrior helmet&rdquo; appearance. (See",
"      <a class=\"local\" href=\"#H12329430\">",
"       '4p deletion syndrome (Wolf-Hirschhorn syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The common clinical features of 7q11.23 deletion syndrome (Williams or Williams-Beuren syndrome, MIM #194050) include cardiovascular and renal abnormalities, failure to thrive, sensorineural hearing loss, constipation, and classical facial features often referred to as &ldquo;elfin facies&rdquo;. (See",
"      <a class=\"local\" href=\"#H12329278\">",
"       '7q11.23 deletion syndrome (Williams syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/1\">",
"      Battaglia A, Hoyme HE, Dallapiccola B, et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics 2008; 121:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/2\">",
"      Gajecka M, Mackay KL, Shaffer LG. Monosomy 1p36 deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/3\">",
"      Heilstedt HA, Ballif BC, Howard LA, et al. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am J Hum Genet 2003; 72:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/4\">",
"      Shapira SK, McCaskill C, Northrup H, et al. Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet 1997; 61:642.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: 1p36 Deletion Syndrome. file://www.ncbi.nlm.nih.gov/books/NBK1191/.",
"    </li>",
"    <li>",
"     Genetics Home Reference: 1p36 deletion syndrome. file://ghr.nlm.nih.gov/condition/1p36-deletion-syndrome (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/7\">",
"      Buck A, du Souich C, Boerkoel CF. Minimal genotype--phenotype correlation for small deletions within distal 1p36. Am J Med Genet A 2011; 155A:3164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/8\">",
"      Brunetti-Pierri N, Berg JS, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008; 40:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/9\">",
"      Mefford HC, Sharp AJ, Baker C, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359:1685.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: 1q21.1 Microdeletion. file://www.ncbi.nlm.nih.gov/books/NBK52787/ (Accessed on December 29, 2011).",
"    </li>",
"    <li>",
"     GeneReviews: Thrombocytopenia Absent Radius syndrome file://www.ncbi.nlm.nih.gov/books/NBK23758/ (Accessed on December 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/12\">",
"      Klopocki E, Schulze H, Strauss G, et al. Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome. Am J Hum Genet 2007; 80:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/13\">",
"      Ward RE, Bixler D, Provisor AJ, Bader P. Parent to child transmission of the thrombocytopenia absent radius (TAR) syndrome. Am J Med Genet Suppl 1986; 2:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/14\">",
"      Albers CA, Paul DS, Schulze H, et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet 2012; 44:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/15\">",
"      Rajcan-Separovic E, Harvard C, Liu X, et al. Clinical and molecular cytogenetic characterisation of a newly recognised microdeletion syndrome involving 2p15-16.1. J Med Genet 2007; 44:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/16\">",
"      Liu X, Malenfant P, Reesor C, et al. 2p15-p16.1 microdeletion syndrome: molecular characterization and association of the OTX1 and XPO1 genes with autism spectrum disorders. Eur J Hum Genet 2011; 19:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/17\">",
"      van Bon BW, Koolen DA, Brueton L, et al. The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype. Eur J Hum Genet 2010; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/18\">",
"      Talkowski ME, Mullegama SV, Rosenfeld JA, et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet 2011; 89:551.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: 2q37 Deletion Syndrome file://www.ncbi.nlm.nih.gov/books/NBK1158/ (Accessed on December 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/20\">",
"      Falk RE, Casas KA. Chromosome 2q37 deletion: clinical and molecular aspects. Am J Med Genet C Semin Med Genet 2007; 145C:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/21\">",
"      Galasso C, Lo-Castro A, Lalli C, et al. Deletion 2q37: an identifiable clinical syndrome with mental retardation and autism. J Child Neurol 2008; 23:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/22\">",
"      Shrimpton AE, Braddock BR, Thomson LL, et al. Molecular delineation of deletions on 2q37.3 in three cases with an Albright hereditary osteodystrophy-like phenotype. Clin Genet 2004; 66:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/23\">",
"      Williams SR, Aldred MA, Der Kaloustian VM, et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am J Hum Genet 2010; 87:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/24\">",
"      Tazelaar J, Roberson J, Van Dyke DL, et al. Mother and son with deletion of 3p25-pter. Am J Med Genet 1991; 39:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/25\">",
"      Nienhaus H, Mau U, Zang KD. Infant with del(3) (p25-pter): karyotype-phenotype correlation and review of previously reported cases. Am J Med Genet 1992; 44:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/26\">",
"      Drumheller T, McGillivray BC, Behrner D, et al. Precise localisation of 3p25 breakpoints in four patients with the 3p-syndrome. J Med Genet 1996; 33:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/27\">",
"      Shuib S, McMullan D, Rattenberry E, et al. Microarray based analysis of 3p25-p26 deletions (3p- syndrome). Am J Med Genet A 2009; 149A:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/28\">",
"      Fernandez TV, Garc&iacute;a-Gonz&aacute;lez IJ, Mason CE, et al. Molecular characterization of a patient with 3p deletion syndrome and a review of the literature. Am J Med Genet A 2008; 146A:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/29\">",
"      Ballif BC, Theisen A, Coppinger J, et al. Expanding the clinical phenotype of the 3q29 microdeletion syndrome and characterization of the reciprocal microduplication. Mol Cytogenet 2008; 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/30\">",
"      Willatt L, Cox J, Barber J, et al. 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet 2005; 77:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/31\">",
"      Estabrooks LL, Rao KW, Driscoll DA, et al. Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. Am J Med Genet 1995; 57:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/32\">",
"      Wright TJ, Ricke DO, Denison K, et al. A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet 1997; 6:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/33\">",
"      Dallapiccola B, Mandich P, Bellone E, et al. Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome. Am J Med Genet 1993; 47:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/34\">",
"      Battaglia A, Filippi T, Carey JC. Update on the clinical features and natural history of Wolf-Hirschhorn (4p-) syndrome: experience with 87 patients and recommendations for routine health supervision. Am J Med Genet C Semin Med Genet 2008; 148C:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/35\">",
"      Nimura K, Ura K, Shiratori H, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009; 460:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/36\">",
"      Zollino M, Murdolo M, Marangi G, et al. On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet 2008; 148C:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/37\">",
"      Hanley-Lopez J, Estabrooks LL, Stiehm R. Antibody deficiency in Wolf-Hirschhorn syndrome. J Pediatr 1998; 133:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/38\">",
"      Battaglia A, Carey JC, Cederholm P, et al. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. Pediatrics 1999; 103:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/39\">",
"      Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/40\">",
"      Kurotaki N, Stankiewicz P, Wakui K, et al. Sotos syndrome common deletion is mediated by directly oriented subunits within inverted Sos-REP low-copy repeats. Hum Mol Genet 2005; 14:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/41\">",
"      Nagai T, Matsumoto N, Kurotaki N, et al. Sotos syndrome and haploinsufficiency of NSD1: clinical features of intragenic mutations and submicroscopic deletions. J Med Genet 2003; 40:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/42\">",
"      Faravelli F. NSD1 mutations in Sotos syndrome. Am J Med Genet C Semin Med Genet 2005; 137C:24.",
"     </a>",
"    </li>",
"    <li>",
"     Genetics Home Reference: Sotos syndrome. file://ghr.nlm.nih.gov/condition/sotos-syndrome (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     GeneReviews: Sotos Syndrome. file://www.ncbi.nlm.nih.gov/books/NBK1479/ (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/45\">",
"      Le Caignec C, De Mas P, Vincent MC, et al. Subtelomeric 6p deletion: clinical, FISH, and array CGH characterization of two cases. Am J Med Genet A 2005; 132A:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/46\">",
"      Maclean K, Smith J, St Heaps L, et al. Axenfeld-Rieger malformation and distinctive facial features: Clues to a recognizable 6p25 microdeletion syndrome. Am J Med Genet A 2005; 132:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/47\">",
"      Tonoki H, Harada N, Shimokawa O, et al. Axenfeld-Rieger anomaly and Axenfeld-Rieger syndrome: clinical, molecular-cytogenetic, and DNA array analyses of three patients with chromosomal defects at 6p25. Am J Med Genet A 2011; 155A:2925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/48\">",
"      DeScipio C. The 6p subtelomere deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/49\">",
"      van der Knaap MS, Kriek M, Overweg-Plandsoen WC, et al. Cerebral white matter abnormalities in 6p25 deletion syndrome. AJNR Am J Neuroradiol 2006; 27:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/50\">",
"      Alward WL. Axenfeld-Rieger syndrome in the age of molecular genetics. Am J Ophthalmol 2000; 130:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/51\">",
"      Nishimura DY, Swiderski RE, Alward WL, et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 1998; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/52\">",
"      Smith RS, Zabaleta A, Kume T, et al. Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. Hum Mol Genet 2000; 9:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/53\">",
"      Morris CA. Introduction: Williams syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:203.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Williams Syndrome. file://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/books/NBK1249/ (Accessed on February 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/55\">",
"      Francke U. Williams-Beuren syndrome: genes and mechanisms. Hum Mol Genet 1999; 8:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/56\">",
"      Marler JA, Sitcovsky JL, Mervis CB, et al. Auditory function and hearing loss in children and adults with Williams syndrome: cochlear impairment in individuals with otherwise normal hearing. Am J Med Genet C Semin Med Genet 2010; 154C:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/57\">",
"      Barozzi S, Soi D, Comiotto E, et al. Audiological findings in Williams syndrome: a study of 69 patients. Am J Med Genet A 2012; 158A:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/58\">",
"      Pober BR. Williams-Beuren syndrome. N Engl J Med 2010; 362:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/59\">",
"      Sakurai T, Dorr NP, Takahashi N, et al. Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions. Autism Res 2011; 4:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/60\">",
"      Mervis CB, John AE. Cognitive and behavioral characteristics of children with Williams syndrome: implications for intervention approaches. Am J Med Genet C Semin Med Genet 2010; 154C:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/61\">",
"      Teebi AS. Nablus mask-like facial syndrome. Am J Med Genet 2000; 95:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/62\">",
"      Raas-Rothschild A, Dijkhuizen T, Sikkema-Raddatz B, et al. The 8q22.1 microdeletion syndrome or Nablus mask-like facial syndrome: report on two patients and review of the literature. Eur J Med Genet 2009; 52:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/63\">",
"      Shieh JT, Aradhya S, Novelli A, et al. Nablus mask-like facial syndrome is caused by a microdeletion of 8q detected by array-based comparative genomic hybridization. Am J Med Genet A 2006; 140:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/64\">",
"      Jain S, Yang P, Farrell SA. A case of 8q22.1 microdeletion without the Nablus mask-like facial syndrome phenotype. Eur J Med Genet 2010; 53:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/65\">",
"      Hall BD, Langer LO, Giedion A, et al. Langer-Giedion syndrome. Birth Defects Orig Artic Ser 1974; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/66\">",
"      Bowen P, Biederman B, Hoo JJ. The critical segment for the Langer-Giedion syndrome: 8q24.11----q24.12. Ann Genet 1985; 28:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/67\">",
"      Parrish JE, Wagner MJ, Hecht JT, et al. Molecular analysis of overlapping chromosomal deletions in patients with Langer-Giedion syndrome. Genomics 1991; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/68\">",
"      Wilson WG, Herrington RT, Aylsworth AS. The Langer-Giedion syndrome: report of a 22-year old woman. Pediatrics 1979; 64:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/69\">",
"      Carvalho DR, Santos SC, Oliveira MD, Speck-Martins CE. Tibial hemimelia in Langer-Giedion syndrome with 8q23.1-q24.12 interstitial deletion. Am J Med Genet A 2011; 155A:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/70\">",
"      Momeni P, Gl&ouml;ckner G, Schmidt O, et al. Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet 2000; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/72\">",
"      Alfi O, Donnell GN, Crandall BF, et al. Deletion of the short arm of chromosome no.9 (46,9p-): a new deletion syndrome. Ann Genet 1973; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/73\">",
"      Christ LA, Crowe CA, Micale MA, et al. Chromosome breakage hotspots and delineation of the critical region for the 9p-deletion syndrome. Am J Hum Genet 1999; 65:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/74\">",
"      Swinkels ME, Simons A, Smeets DF, et al. Clinical and cytogenetic characterization of 13 Dutch patients with deletion 9p syndrome: Delineation of the critical region for a consensus phenotype. Am J Med Genet A 2008; 146A:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/75\">",
"      Harada N, Visser R, Dawson A, et al. A 1-Mb critical region in six patients with 9q34.3 terminal deletion syndrome. J Hum Genet 2004; 49:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/76\">",
"      Stewart DR, Huang A, Faravelli F, et al. Subtelomeric deletions of chromosome 9q: a novel microdeletion syndrome. Am J Med Genet A 2004; 128A:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/77\">",
"      Verhoeven WM, Egger JI, Vermeulen K, et al. Kleefstra syndrome in three adult patients: further delineation of the behavioral and neurological phenotype shows aspects of a neurodegenerative course. Am J Med Genet A 2011; 155A:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/78\">",
"      Stewart DR, Kleefstra T. The chromosome 9q subtelomere deletion syndrome. Am J Med Genet C Semin Med Genet 2007; 145C:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/79\">",
"      Kleefstra T, van Zelst-Stams WA, Nillesen WM, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet 2009; 46:598.",
"     </a>",
"    </li>",
"    <li>",
"     Genetics Home Reference: Kleefstra syndrome. file://ghr.nlm.nih.gov/condition/kleefstra-syndrome (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/81\">",
"      Greenberg F, Valdes C, Rosenblatt HM, et al. Hypoparathyroidism and T cell immune defect in a patient with 10p deletion syndrome. J Pediatr 1986; 109:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/82\">",
"      Monaco G, Pignata C, Rossi E, et al. DiGeorge anomaly associated with 10p deletion. Am J Med Genet 1991; 39:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/83\">",
"      Obregon MG, Mingarelli R, Giannotti A, et al. Partial deletion 10p syndrome. Report of two patients. Ann Genet 1992; 35:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/84\">",
"      Schuffenhauer S, Seidel H, Oechsler H, et al. DiGeorge syndrome and partial monosomy 10p: case report and review. Ann Genet 1995; 38:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/85\">",
"      Shapira M, Borochowitz Z, Bar-El H, et al. Deletion of the short arm of chromosome 10 (10p13): report of a patient and review. Am J Med Genet 1994; 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/86\">",
"      Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000; 406:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/87\">",
"      Br&eacute;mond-Gignac D, Crolla JA, Copin H, et al. Combination of WAGR and Potocki-Shaffer contiguous deletion syndromes in a patient with an 11p11.2-p14 deletion. Eur J Hum Genet 2005; 13:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/88\">",
"      Chien WH, Sue WC, Kuo PL, et al. Potocki-Shaffer syndrome: report of one case. Acta Paediatr Taiwan 2003; 44:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/89\">",
"      Romeike BF, Wuyts W. Proximal chromosome 11p contiguous gene deletion syndrome phenotype: case report and review of the literature. Clin Neuropathol 2007; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/90\">",
"      Hall CR, Wu Y, Shaffer LG, Hecht JT. Familial case of Potocki-Shaffer syndrome associated with microdeletion of EXT2 and ALX4. Clin Genet 2001; 60:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/91\">",
"      Wu YQ, Badano JL, McCaskill C, et al. Haploinsufficiency of ALX4 as a potential cause of parietal foramina in the 11p11.2 contiguous gene-deletion syndrome. Am J Hum Genet 2000; 67:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/92\">",
"      Kim HG, Kim HT, Leach NT, et al. Translocations disrupting PHF21A in the Potocki-Shaffer-syndrome region are associated with intellectual disability and craniofacial anomalies. Am J Hum Genet 2012; 91:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/93\">",
"      Swarr DT, Bloom D, Lewis RA, et al. Potocki-Shaffer syndrome: comprehensive clinical assessment, review of the literature, and proposals for medical management. Am J Med Genet A 2010; 152A:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/94\">",
"      Favier R, Jondeau K, Boutard P, et al. Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. Thromb Haemost 2003; 90:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/95\">",
"      Grossfeld PD, Mattina T, Lai Z, et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 2004; 129A:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/14/34025/abstract/96\">",
"      Tyson C, Qiao Y, Harvard C, et al. Submicroscopic deletions of 11q24-25 in individuals without Jacobsen syndrome: re-examination of the critical region by high-resolution array-CGH. Mol Cytogenet 2008; 1:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16660 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34025=[""].join("\n");
var outline_f33_14_34025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86271084\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2472601\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4404114\">",
"      OVERVIEW OF GENOMIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H627264199\">",
"      1p36 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86260767\">",
"      1q21.1 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86260827\">",
"      DISTAL 1q21 DELETION SYNDROME (THROMBOCYTOPENIA-ABSENT RADIUS SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6403043\">",
"      2p15-16.1 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6403059\">",
"      2q23.1 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86260896\">",
"      2q37 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12329301\">",
"      3p DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86260980\">",
"      3q29 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12329430\">",
"      4p DELETION SYNDROME (WOLF-HIRSCHHORN SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12329086\">",
"      5q35 DELETION SYNDROME (SOTOS SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86261072\">",
"      6p25 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12329278\">",
"      7q11.23 DELETION SYNDROME (WILLIAMS SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86261212\">",
"      8q22.1 DELETION SYNDROME (NABLUS MASK-LIKE FACIAL SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2473563\">",
"      8q24.11 DELETION SYNDROME (LANGER-GIEDION SYNDROME OR TRICHORHINOPHALANGEAL SYNDROME TYPE II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6403159\">",
"      9p22 DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86261300\">",
"      9q34.3 DELETION SYNDROME OR 9q SUBTELOMERE DELETION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86261405\">",
"      10p14-p13 DELETION (DiGEORGE SYNDROME TYPE II)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2473577\">",
"      11p13 DELETION SYNDROME (WAGR SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86261562\">",
"      11p11.2 DELETION SYNDROME (POTOCKI-SHAFFER SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2473584\">",
"      11q24.1 DELETION SYNDROME (JACOBSEN SYNDROME)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86271084\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16660|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/28/41412\" title=\"figure 1\">",
"      Nonhomologous recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/63/29687\" title=\"figure 2\">",
"      Schematic CGH for microarray setup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/17/37143?source=related_link\">",
"      Microduplication syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10024?source=related_link\">",
"      Sex chromosome abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_14_34026="Pleural hematoma I CT";
var content_f33_14_34026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69148%7EPULM%2F56387%7EPULM%2F81933%7EPULM%2F60640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69148%7EPULM%2F56387%7EPULM%2F81933%7EPULM%2F60640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large pleural hematoma after trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan performed without intravenous injection of contrast material shows inhomogeneous opacification of the right hemithorax with mostly higher attenuation material. A right-sided chest tube is in place. Cardiomediastinal shift to the left is seen. The interventricular cardiac septum is seen as a higher attenuation structure when compared to the interventricular blood. This suggests a severe dilutional anemia due to severe hemorrhage with a hemoglobin level of less than 7 g/dL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural hematoma in right hemithorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spontaneous hemorrhage in an anticoagulated patient. The right effusion has high attenuation due to the fresh blood. The left pleural effusion is transudative and has lower attenuation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loculated pleural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loculated pleural hematoma in left hemithorax after CABG. The loculated collection of blood has higher attenuation than the chest wall musculature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected pleural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loculated collection of blood with fresh thrombus exhibiting higher attenuation. Bubbles of gas are likely due to gas-forming organisms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34026=[""].join("\n");
var outline_f33_14_34026=null;
var title_f33_14_34027="Chronic migraine diagnostic criteria";
var content_f33_14_34027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised International Headache Society criteria for chronic migraine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A. Headache (tension-type and/or migraine) on &ge;15 days per month for at least three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Occurring in a patient who has had at least five attacks fulfilling criteria for migraine without aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. On &ge;8 days per month for at least three months, headache has fulfilled C1 and/or C2 below, that is, has fulfilled criteria for pain and associated symptoms of migraine without aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C1. Has at least two of the following",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a) Unilateral location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b) Pulsating quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c) Moderate or severe pain intensity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d) Aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        and at least one of the following",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        e) Nausea and/or vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        f) Photophobia and/or phonophobia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C2. Treated and relieved by triptan(s) or ergot before the expected development of C1 above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. No medication overuse and not attributed to another causative disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742. Copyright &copy; 2006 Sage Publications. Reprinted by permission of Sage.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34027=[""].join("\n");
var outline_f33_14_34027=null;
var title_f33_14_34028="Proposed diagnostic criteria for short QT syndrome";
var content_f33_14_34028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed diagnostic criteria for short QT syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        QTc, msec",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;370",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;350",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;330",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jpoint-Tpeak interval &lt;120 msec",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical history*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of sudden cardiac arrest",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Documented polymorphic VT or VF",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unexplained syncope",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Family history*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        First- or second-degree relative with high probability of SQTS",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        First- or second-degree relative with autopsy-negative sudden cardiac death",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sudden infant death syndrome",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Genotype*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genotype positive",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mutation of undetermined significance in a culprit gene",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    High-probability SQTS: &ge;4 points.",
"    <br>",
"     Intermediate-probability SQTS: 3 points.",
"     <br>",
"      Low-probability SQTS: &le;2 points.",
"      <div class=\"footnotes\">",
"       <br>",
"        VF: ventricular fibrillation; VT: ventricular tachycardia; SQTS: short QT syndrome; QT: Bazett corrected QT interval; msec: milliseconds.",
"        <br>",
"         <br>",
"          * A minimum of 1 point must be obtained in the electrocardiographic section in order to obtain additional points.",
"         </br>",
"        </br>",
"       </br>",
"      </div>",
"      <div class=\"reference\">",
"       <br>",
"        Original table modified for this publication. Gollob MH, Redpath CJ, Roberts JD: The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011; 57:802. Table used with the permission of Elsevier Inc. All rights reserved.",
"       </br>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34028=[""].join("\n");
var outline_f33_14_34028=null;
var title_f33_14_34029="Eval risk factor CHD DM I";
var content_f33_14_34029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63757%7ECARD%2F72498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63757%7ECARD%2F72498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of major risk factors for coronary heart disease in patients with diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cigarette smoking",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        History:",
"       </strong>",
"       Record current and past smoking habits; list smoking duration (years of use) and intensity (number of cigarettes smoked per day); determine passive smoke exposure (at work and at home).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Blood pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        History:",
"       </strong>",
"       Record history of blood pressure (BP) and measures of treatment, including current and past antihypertensive drug therapy. Also determine acquired factors affecting BP: body weight, physical activity level, sodium intake, and alcohol consumption.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Physical examination:",
"       </strong>",
"       Define current BP from multiple measurements; measure BP supine, sitting, and standing in elderly patients; consider 24-hour automated, ambulatory BP monitoring in older patients (detects absence of nocturnal fall in BP [autonomic dysfunction], episodic hypertension, orthostatic hypertension, resistant hypertension).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Serum lipids and lipoproteins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        History:",
"       </strong>",
"       Assess dietary habits and alcohol intake, exercise habits, efforts to modify lifestyle habits, use of medications that influence serum lipoprotein values, family history of premature vascular disease and dyslipidemia, history of thyroid disorders or pancreatitis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Physical examination:",
"       </strong>",
"       Check for eruptive xanthomas and lipemia retinalis (signs of severe hypertriglyceridemia), tuberoeruptive xanthomas (sign of dysbetalipoproteinemia), xanthelasma (suggestive of hyperlipidemia), and signs of hypothyroidism.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Laboratory:",
"       </strong>",
"       Measure fasting serum total cholesterol, LDL cholesterol, HDLcholesterol, triglycerides; (optional: apolipoprotein B*, lipoprotein[a], LDL size), thyroid, renal, liver function tests.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Albuminuria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Measure serum creatinine.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Test urine for protein with a dipstick: If dipstick is negative, measure urine albumin-to-creatinine ratio in the first-morning urine specimen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Glycemic status",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        History:",
"       </strong>",
"       Age of onset of hyperglycemia; course of diabetes treatment; family history of diabetes, history of diabetic complications.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Physical examination:",
"       </strong>",
"       Cardiovascular status, retinopathy, other diabetic complications.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Laboratory:",
"       </strong>",
"       Measure fasting blood glucose; hemoglobin A1c (periodically).",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Apolipoprotein B is especially useful if triglycerides are elevated but LDL cholesterol is in the normal range.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy, SM, Benjamin, IJ, Burke, GL, et al. Circulation 1999; 100:1134.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of predisposing risk factors in patients with diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"        Body weight and fat distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess history of body weight, age at onset of overweight, history of weight loss and",
"weight gain; assess eating and exercise habits, social and occupational",
"factors affecting body weight, family support, history of body weights",
"in family members in childhood and adulthood, attitudes and motivation",
"for weight control.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Physical examination:",
"        </strong>",
"        Measure body weight (kg) and height (m); calculate body mass index (BMI) (kg/m2); categorize body weight (BMI 25 to 29.9 = overweight; &ge;30 = obesity); measure waist circumference (abdominal obesity &ge;40 in [102 cm] in men or &ge;36 in [88 cm] in women; borderline abdominal obesity in men, 88 to 102 cm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess past and current levels of",
"physical activity; ascertain activity on the job, participation in",
"sports, regular walking, jogging, or swimming. In women, ask about",
"activity in housework, child care; determine opportunities and",
"available facilities for regular exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Physical examination:",
"        </strong>",
"        Assess level of cardiovascular fitness in cardiac rehabilitation facilities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess family history for",
"cardiovascular disease (CVD) or sudden death. (Family history is",
"positive if CVD or sudden death occurred in first-degree male relatives",
"before age 55 years or first-degree female relatives before age 65",
"years.) Determine presence or absence of other risk factors - high",
"serum cholesterol values, cigarette smoking, hypertension, diabetes -",
"in first-degree relatives (biological parents, siblings, offspring). If",
"possible, expand family tree to second-degree relatives (grandparents,",
"uncles, aunts). Create a simple family tree.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Laboratory:",
"        </strong>",
"        Measure blood glucose and serum lipids (cholesterol, triglycerides, and HDL cholesterol) in first-degree relatives.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy, SM, Benjamin, IJ, Burke, GL, et al. Circulation 1999; 100:1134.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34029=[""].join("\n");
var outline_f33_14_34029=null;
var title_f33_14_34030="Leukemic infiltrate";
var content_f33_14_34030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukemic cells in the vitreous of a boy with relapse of acute lymphoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman, W, Jaeger, E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34030=[""].join("\n");
var outline_f33_14_34030=null;
var title_f33_14_34031="Hot tub folliculitis";
var content_f33_14_34031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hot tub folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This form of folliculitis is caused by Pseudomonas aeruginosa and can occur after exposure to hot tubs or whirlpools.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_14_34031=[""].join("\n");
var outline_f33_14_34031=null;
